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Summary 
TGF-β1 is a key player in the onset, the progress, and end stages of CLD promoting fibrogenesis and 
tumorigenesis. To date, the expression and function of TGF-β2 have not been investigated thoroughly in 
liver disease. In this thesis, we provide evidence that TgfB2 and not, as formerly known, only TgfB1 
correlate with fibrogenesis and liver cancer development.  
In a comparative analysis, we analyzed TgfB2 and TgfB1 expression and secretion in murine and human 
HSCs, hepatocytes, and HCC/hepatoblastoma cell lines. In various mouse models reflecting regeneration, 
acute and chronic liver disease, and human HCC sample cohorts, we demonstrated that both isoforms are 
expressed in different types of liver cells and that expression is elevated during the progression of CLD in 
mouse models in most cases. Although TgfB2 is mostly secreted at lower levels than TgfB1, its expression 
patterns largely follow similar profiles. However, the secretion of TgfB2 exceeded that of TgfB1 in some 
HCC cell lines. Our data indicates a more prominent implication of TgfB2 in biliary-derived liver disease 
models. 
In this thesis, the anti-fibrotic and immunoregulatory effects of TgfB2 silencing in cholestatic MDR2-KO 
mice have been delineated for the first time. TgfB2 silencing by AONs specifically reduced collagen 
deposition and αSMA expression, but induced anti-fibrotic PparG expression. Accumulation of TGF-β2-
specific AON was detected in macrophage-activated fibroblasts, LSEC, and activated HSCs in mice. This 
was in accordance with TgfB2 expression in these cell types. CD45-positive immune cell infiltration was 
reduced upon TGF-β2-specific AON treatment in the livers of MDR2-KO mice. Furthermore, TGF-β2 levels 
were found to be elevated and correlated with CD45-positive immune cell infiltration in PSC and PBC 
patients.  
In summary, the data presented, provides a strong rationale to examine anti-TgfB2-directed treatment in 
patients with cholestatic liver damage as PSC or PBC.  
Taken together, this thesis points towards TGF-β2 as a promising therapeutic target in CLD especially of 
biliary origin. It provides a direct rationale for TGF-β2-directed drug development an further suggests to 
initiate a clinical trial testing TGF-β2 inhibition in PSC and PBC patients. 
II 
Zusammenfassung 
TGF-β1 ist ein Hauptakteur, der an der Entstehung, der Entwicklung und an Endstadien von chronischen 
Lebererkrankungen beteiligt ist, in dem er den Prozess der Fibrogenese und der Tumorentstehung 
begünstigt. Bislang ist die Expression und Funktion von TGF-β2 in Lebererkrankungen weitgehend 
unerforscht. Diese Dissertation zeigt auf, dass auch TGF-β2 und nicht nur TGF-β1, wie bisher 
angenommen, an der Fibrogenese und Leberkrebsentstehung Anteil hat.  
In einer vergleichenden Studie haben wir die Expression und Sekretion von TGF-β2 und TGF-β1 in murinen 
und humanen Sternzellen, Hepatozyten und HCC/Hepatoblaston-Zelllinien analysiert. In verschiedenen 
Mausmodellen für Regeneration, akute wie auch chronische Leberschädigung und in humanen HCC-
Patienten-Kollektiven haben wir zeigen können, dass beide Isoformen in den verschiedenen 
Leberzelltypen exprimiert sind und das ihre Expression im Verlauf der chronischen Lebererkrankung in den 
meisten Mausmodellen zunimmt. Die Sekretion von TGF-β2 war in den meisten Fällen geringer im 
Vergleich zu TGF-β1, jedoch verhält sich die Expression beider Zytokine sehr ähnlich. In einigen HCC-
Zelllinien überstieg die Menge an sekretiertem TGF-β2 sogar die von TGF-β1. Unsere Analysen zeigten, 
dass TGF-β2 in Mausmodellen mit biliärer Leberschädigung eine prominentere Rolle als TGF-β1 einnahm. 
Mit dieser Arbeit wurden erstmalig die antifibrotischen und immunregulatorischen Effekte nach TGF-β2-Inhibition im 
cholestatischen MDR2-KO-Mausmodell beschrieben. Die Inhibition von TGF-β2 durch AONs verminderte 
besonders die Kollagenablagerung und die αSMA-Expression. Ebenso wurde der antifibrotische wie auch 
anti-inflammatorische Marker PparG induziert. Das TGF-β2-spezifische AON konnte in LSEC, durch 
Makrophagen-aktivierten Fibroblasten und in aktivierten Sternzellen von Mäusen nachgewiesen werden. 
Auch die Expression von TGF-β2 war in diesen Leberzelltypen entsprechend nachweisbar. Der Pan-
Neutrophilmarker CD45 war nach Behandlung mit dem TGF-β2-spezifischen AON in MDR2-KO-Mäusen 
deutlich reduziert. In Patienten mit Primär sklerosierende Cholangitis (PSC) und Primär biliäre Cholangitis 
(PBC) waren die TGF-β2-Werte erhöht und korrelierten mit der Expression von CD45-positiven 
Immunzellen. 
Zusammenfassend bieten die Daten dieser Dissertation vielversprechende Gründe, um eine anti- TGF-β2- 
gerichtete Behandlung in Patienten mit cholestatischer Leberschädigung wie PSC oder PBC zukünftig zu 
untersuchen. Mit dem Wissen, dass es bislang keine kurative Behandlung für Patienten mit dieser seltenen, 
III 
jedoch destruktiven Erkrankung gibt, zeigt sich TGF-β2 als eine aussichtsreiches therapeutische 
Zielstruktur für die Behandlung biliärer Leberschädigung. 
IV 
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1 Introduction 
1.1 Transforming Growth Factor-β (TGF-β) in Chronic Liver Diseases (CLD) 
and Hepatocellular Carcinoma (HCC) 
Currently, liver resection followed by a transplantation is the mainstay option for fighting terminal liver 
failure, yet the prognosis continues to be poor [1]. The demand for new therapies increases due to the lack 
of donor organs, which leads to a major medical problem. In chronic liver disease (CLD), tissue remodeling 
and wound healing are interrupted, resulting in complex modulation of the signaling processes at the 
cellular and molecular level. Subsequent fibrosis leads to the onset of hepatic disease development 
including cirrhosis, HCC, or hepatic failure. In this multi-step process, TGF-β plays a pivotal regulatory role, 
contributing to all stages of disease progression [2]. 
1.1.1 The TGF-β superfamily 
The TGF-β superfamily is composed of about 33 structurally related secretory proteins. It includes groups of 
TGF-β isoforms, activins, nodals, as well as the larger group of bone morphogenetic proteins (BMPs) [3]. 
Originally, TGF-β was discovered as a transforming factor in cell-conditioned media from sarcoma mouse 
fibroblasts, which induced the growth of adherent cells [4]. Adhesion, differentiation, cell growth, 
migration, and embryonal development are regulated by TGF-β family members in a cell-type-specific and 
context-dependent manner. Their role is bidirectional, e.g., they are involved in both the promotion and 
inhibition of cancer progression [5]. They are also found in various other human diseases [6]. 
The three TGF-β isoforms (TGF-β1, TGF-β2, and TGF-β3) exist as homodimers in mammals. They are 
synthesized as precursors and then secreted as latent homodimeric complexes incorporated into the ECM. 
By proteolytic cleavage, they are activated and can then act on their target cells [2]. During secretion, the 
c-terminal TGF-β molecule remains bound to the N-terminus of the precursor, forming the latency-
associated peptide (LAP). The LAP forms larger complexes with certain members of the latent TGF-β 
binding protein family (LTBP) that confer extracellular matrix interaction. Certain proteases, pH changes, 
competition of particular matrix components, and others induce the release of TGF-β isoforms from the 
LAP [7, 8]. Furthermore, TGF-β isoform activation requires integrin binding since it is expressed in an 
inactive or latent form [9]. 
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Generally, TGF-β family members have about 66 to 80% sequence identity. The TGF-β1 and TGF-β2 
isoforms are closely related and share about 70% of their amino acid sequence homology [10, 11]. All TGF-
β ligands exert their effects on cells by signaling through a heterotetrameric receptor signaling system [12]. 
The complex of ligand–receptor interactions is able to initiate various downstream signaling pathways. 
The specificity of ligands at the receptor level is provided by a limited number of type II, type I, and 
accessory receptors (Figure 1). Various combinations occur at the level of ligand–receptor interactions and 
at the level of type II–type I receptor interactions [13, 14].The TGF-β receptors type I and II (TGFβRI, 
TGFβRII) are present in most mammalian cell types, including cancer cells [15]. TGFβR-I and -II are essential 
for provoking the biological response after the binding of a TGF-β ligand [8]. TGFβRII is activated via 
phosphorylation and subsequently phosphorylates TGF-β receptor type I. The TGF-β mediated activation 
of the ligand receptor complex signal through two autonomously working TGFβRI:TGFβRII pairs [16]; 
TGFβRI, in turn, phosphorylates intracellular mediators such as receptor (R)-Smads [17] and other effectors 
[18]. These complexes are translocated to the nucleus where they regulate the transcription of target 
genes [19]. The binding affinity of the TGF-β isoforms to the receptors differs. TGF-β3 and TGF-β1 bind 
TGFβRII with higher affinity [20-22], whereas Betaglycan and Endoglin (also known as TGFβRsIII) stabilize 
TGF-βs in a conformation optimal for binding to the signaling receptors. Betaglycan binds all TGF-β 
isoforms with high affinity [23] and significantly augments the binding efficacy of TGF-β2 to TGFβRII [24]. 
Its relative Endoglin only binds TGF-β1 and TGF-β3, but not TGF-β2 [25] . Thus, both co-receptors serve as 
modulators of the TGF-β isoform-receptor interaction and the responsiveness of the cells. 
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Figure 1 Schematic representation of the TGFβ-Smad signaling pathway [13] in mammalians. 
 
1.1.2 Biological functions of the TGF-β isoforms  
All three TGF-β isoforms modulate apoptosis, proliferation, differentiation, migration, and invasion and 
share partly overlapping but non-redundant functions. 
1.1.2.1 The TGF-β1 isoform  
Mouse models have been developed to unravel the functions of TGF-β. About 60% of homozygous TGF-
β1null mice already die in utero due to deficient hematopoiesis and vasculogenesis, which underlines its 
function in embryogenesis and development. The other 40%, the surviving mice, develop multifocal 
inflammatory responses and tissue necrosis in the heart, liver, pancreas, and other organs, which leads to 
organ failure and death within less than one month. In the livers of these mice, altered phenotypes of 
hepatocytes and increased numbers of mitochondria in response to stress were found [26-29]. TGF-β1 is a 
multifunctional cytokine and plays a pivotal role in maintaining tissue homeostasis. It is involved in the 
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development of tissue fibrosis, where it is a strong stimulator of extracellular matrix (ECM) deposition. 
TGF-β1-mediated synthesis and accumulation of ECM components and the reduction of matrix 
metalloproteinases (MMPs) degradation [30] are common hallmarks of this isoform. In cancer, TGF-β1 has 
ambiguous functions: In early stages, it acts as a tumor suppressor, but in later stages it is often described 
as being a tumor promoter [5, 31, 32], with TGF-β1 being the most widely investigated isoform in many 
human cancers [33].  
 
1.1.2.2 The TGF-β2 isoform 
TGF-β2 also seems to be a mediator of developmental processes. TGF-β2null mice exhibit perinatal mortality 
and developmental defects in cardiac, lung, craniofacial, limb, spinal column, eye, inner ear, and urogenital 
tissues. Developmental defects of mice lacking TGF-β2 are mainly caused by altered epithelial-
mesenchymal interactions, cell growth, extracellular matrix production, and tissue remodeling [34, 35]. 
Gremlin-mediated TGF-β2 expression was found to modulate the ECM of cells and tissue in glaucoma by 
increasing the expression of a variety of ECM proteins [36].Wick et al. [37] demonstrated that TGF-β2-
mediated MMP-2 and MMP-9 expression induction along with suppressed tissue inhibition of 
metalloproteinase (TIMP)-2 expression facilitated invasion of cancer cells. In fibrosis-related cell types such 
as fibroblasts, TGF-β2 and TGF-β3 have shown profibrotic effects in vitro [38]. In view of that, TGF-β2 has 
been described as being involved in the activation of mesenchymal cells and in matrix production in fibrotic 
livers [39]. The role of TGF-β2 as an ECM modulator was strengthened by studies of glaucoma and 
mammary gland cells where its induction was accompanied by cell morphology changes and correlation 
with a mesenchymal phenotype [40]. Inhibition of microRNA-29, which is a negative regulator of ECM, led 
to TGF-β2 upregulation, where it contributed to the expression of several ECM components [41]. 
In cancer, there exists little information about TGF-β2. It was first described as a secreted peptide of human 
glioma cells suppressing the effects of interleukin 2-dependent T-cell growth [42]. Along with this finding, 
speculation about the immunosuppressive effects induced by TGF-β2 started. Its overexpression probably 
leads to a mechanism by which tumor cells can escape from immune surveillance. TGF-β2 is released by 
tumors of several origins, including glioblastomas, breast cancer, melanoma, and others [43]. In pancreatic 
cancer and high-grade glioma, TGF-β2 was found to be one key factor driving the immunosuppressive 
phenotype of patients and its overexpression correlated with poor clinical outcome [44, 45]. 
TGF-β3 knockout mice have shown defects in morphogenesis of the palate and the lungs, evidenced in mice 
by abnormal lung development and cleft palate and implicating the involvement of TGF-β3 in epithelial-
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mesenchymal interactions [35, 46]. It seems that there are no or only a few phenotypic overlaps with all 
three-null mice, indicating numerous non-compensated functions [34]. 
1.1.3 TGF-β1 and TGF-β2 in liver and chronic liver disease (CLD) 
TGF-β represents a key cytokine in liver, liver fibrosis, and subsequently in cirrhosis and HCC. Upon liver 
damage, TGF-β gets activated and mediates a series of cellular events during every progression stage of 
the disease, starting from hepatic stellate cell activation and ending with hepatocyte death and EMT 
(Figure 2). 
 
Figure 2 Adverse and beneficial impacts of TGF-β during the progression of chronic liver diseases [47].  
All TGF-β isoforms are present in the liver, but their expression is not homogeneously distributed among all 
cell types. In the normal liver, expression of TGF-β1 and TGF-β2 was found enriched in isolated sinusoidal 
endothelial and Kupffer cells of rats [48]. Milani et al. [49] describe low expression of TGF-β1 solely in some 
portal tract stromal cells, and TGF-β2 mRNA was not detectable in normal human and rat livers as 
examined using in-situ hybridization and immunostaining. In human and rat fibrotic livers, TGF-β1 was 
detectable in portal tract cells, as well as in inflammatory and surrounding bile duct cells, whereas TGF-β2 
showed a remarkably different pattern and was exclusively found in proliferation bile duct cells. In studies 
by De Bleser et al. [50], TGF-β1 was the most abundant isoform in normal and fibrotic rat livers, strongly 
expressed in Kupffer cells and moderately expressed by hepatic stellate cells. In the same context, TGF-β2 
was highest in Kupffer cells and, to a minor extent, in stellate and endothelial cells, which confirms the 
results found in the studies of Bissell et al. and Milani et al. Examining two other liver injury models with 
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respect to TGF-β isoform expression, Bissel et al. [48] could confirm strong TGF-β2 expression in bile duct 
ligated rat livers, giving it a specific role in biliary-derived liver disease. Interestingly, although hepatocytes 
do not seem to synthesize TGF-β, significant amounts of latent TGF-β were found to be stored in their 
cytoplasm [51].  
Chronic liver injury is characterized by continuous hepatocyte damage, death, and TGF-β1- driven stellate 
cell activation followed by myofibroblast transdifferentiation. Alterations of the extracellular matrix and 
thus the microenvironment are not only a hallmark of liver fibrogenesis but also a key event in liver cancer, 
as more than 80% of tumors arise from a background of chronic inflammation accompanied by liver 
fibrosis/cirrhosis [52]. Liver cancer comprises diverse primary hepatic neoplasms including hepatocellular 
carcinoma (HCC) and intrahepatic bile duct carcinoma (cholangiocarcinoma) (CCC). The expression of 
TGF-β isoforms is relevantly increased in hepatocellular carcinoma (HCC). All three TGF-β isoforms and 
their receptors in human HCC were found overexpressed in comparison to controls. Intense 
immunohistochemical staining of TGF-β isoforms was found in malignant hepatocytes and stromal cells, 
suggesting autocrine and paracrine pathways [53].  
The molecular heterogeneity and thus the pathogenesis of HCC makes it very complex to generate suitable 
classifications and prognostic estimations for HCC patients. In Coulouarn et al. [54], a TGF-β-specific gene 
expression signature was defined and two homogeneous HCC groups were associated with so-called early 
and late TGF-β signatures. Increased invasiveness and recurrence appeared in tumors expressing late TGF-
β-responsive genes. The expression signatures in HCC patients showed in most cases a more prominent 
role of TGF-β1 during disease development. Little is known, however, about TGF-β2 in this setting. The 
characterization of other intrahepatic malignant tumors such as cholangiocarcinomas (CC) or 
hepatocholangiocarcinomas (cHCC-CC), TGF-β2 comes to the mind. These tumors display biliary-derived 
perturbations and features of HCC formation. Gene analysis of hepatocholangiocarcinomas (cHCC-CC) has 
revealed various pro-fibrotic genes, including TGF-β1 and significantly upregulated TGF-β2. Further genes 
related to extracellular matrix (ECM) remodeling and biliary connection were found enhanced [55], which 
again indicates TGF-β-specific involvement in ECM rearrangements and biliary dysfunction. As a top-
ranked gene, TGF-β2 has been described in high stromal expression along with poor prognosis in 
intrahepatic cholangiocarcinomas (ICC) [56]. In addition, a study from 2003 confirmed the overexpression 
of TGF-β2 and TGF-β3, but not TGF-β1 in cholangiocarcinoma [57].  
Nevertheless, in human liver disease little is known about TGF-β2 and its functions in CLD. Research 
primarily focuses on TGF-β1, which is examined extensively in healthy liver and chronic liver disease. But 
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the abundance of TGF-β2 and the strong expression mainly cholestasis damaged livers makes it a 
druggable target, and only minor off-target effects are expected.  
1.1.4 Therapeutic targeting of TGF-β signaling in CLD of mice and men  
Once the role of at least TGF-β1 became clearer in cancer and fibrosis, great efforts have been undertaken 
to create sophisticated tools inhibiting the TGF-β pathway in disease. The number of possible compounds 
for treating chronic liver disease already at the onset of the disease using personalized approaches has 
increased in recent years [58, 59]. On the basis of observations, where TGF-β1 was found to act as a 
multifunctional cytokine, several strategies have been developed to block the TGF-β pathway. These 
include (1) ligand traps and peptides, (2) monoclonal antibodies, (3) antisense oligonucleotides, (4) small-
molecule inhibitors, and (5) others [47, 59].  
One of the best-studied approaches in regard to preclinical liver fibrosis is TGF-β inhibition using ligand traps 
and peptides, and in particular a soluble TβRII receptor fragment. This antagonist, which exerts the 
extracellular part of the TβRII receptor, interferes with ligand binding to the endogenous receptor complex 
and has been able to inhibit fibrotic markers in mice and rats with chemically induced fibrosis via CCl4 and 
dimethylnitrosamine (DEN) or bile duct ligation. Interestingly, Nakamura et al. [60] were able to 
demonstrate inhibition of hepatic alterations via muscle-applied TβRII receptor compound delivery [60-
63]. In liver disease, further experimental studies have been undertaken using galunisertib (LY2157299 
monohydrate), a small molecule ALK5 inhibitor, in MDR2-KO mice with cholestatic liver damage. In this 
study, TGF-β inhibition by galunisertib did reduce CLD progression by modulating ECM components and 
not directly by reducing the stages of liver fibrosis [64]. Currently, a phase 1/2 dose escalation and safety/ 
tolerability trial in patients with advanced recurrent hepatocellular carcinoma, solid tumor and non-small 
cell lung cancer is ongoing (NCT02423343) in which the LY2157299 compound has been already tested for 
safety, tolerability, and efficacy in glioma [65]. 
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Figure 3 Scheme of therapeutic interventions for the TGF-β signal transduction pathway and targets [59]. 
In contrast to the promising anti-TGF-β treatment in preclinical disease models, only limited or even adverse 
results have been shown to date for human disease [47]. Some studies were stopped since patients died, 
e.g., due to application difficulties or incompatibility [66] (NCT00761280). Others are still ongoing and the 
results are pending. Multifarious tools for TGF-β ligand inhibition are available, among them several 
blocking antibodies, such as CAT-192 for TGF-β1 (NCT00043706) or CAT-152 for TGF-β2 [67, 68]. Trapping 
the TGF-β ligands TGF-β1 or TGF-β2 by using the aforementioned antibodies has been tested in renal 
fibrosis or systemic sclerosis in vivo, but none of them in liver-related diseases. Intriguingly, antisense 
oligonucleotides (AONs) have been progressed the furthest in terms of clinical testing and development 
and have shown successful anti-TGF-β2 inhibition when a specific AON (Figure 4) was used in the 
treatment of glioma [69] and cancers such as pancreatic carcinoma [70], colon carcinoma, and melanoma 
[71]. Other interesting anti-TGF-β2 antisense approaches are the generation of tumor vaccines by AON-
transfected allogeneic non-small-cell lung cancer (NSCLC) cells, which are then injected into the subject. 
A study by Bazhenova in 2012 was able to show that TGF-β2-antisense gene-modified NSCLC cells helped 
patients acquire a significant dose-related survival difference, allowing the trial to progress to a phase III 
 12 
clinical trial (NCT00676507) [72-74]. Drug delivery issues and application problems could be bypassed by 
using these TGF-β-inhibited, engineered tumor-specific cell lines. 
Specific targeting of TGF-β members known to foster the complicated mechanism of liver fibrosis seems to 
be an important step forward in regard to treatment perspectives. Future aims may be the increase of drug 
efficacy and the avoidance of possible side effects due to systemic inhibition. Thus, a major therapeutic 
goal is the reduction, but not the complete ablation of TGFβ signaling in the body/organ/system, since 
TGF-βs have adverse as well as beneficial outcomes. The aforementioned issues may be the reason why 
many of the promising preclinical results from animal disease models could not be translated directly into 
clinical use. 
Despite many unresolved questions, antisense oligonucleotides (AONs) present an eminent therapeutic 
potential. With the availability to a specific human and murine anti-TGF-β2-directed antisense 
oligonucleotide we aim to silence and investigate TGF-β2 in a mouse model for cholestatic liver disease.  
 
Figure 4 Schematic representation of the antisense oligonucleotides (AONs) mechanism of action in a mammalian 
cancer cell (Copyright, all rights reserved by Isarna Therapeutics, formerly Antisense Pharma). 
1.1.5 TGF-β 2 in primary sclerosing cholangitis (PSC) and primary biliary cirrhosis (PBC)  
Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, and primary sclerosing 
cholangitis (PSC) belong to the category of rare chronic autoimmune liver diseases initiated by 
inflammation that ultimately destroy the biliary system. The impaired bile formation results in 
parenchymal damage at the level of the hepatocytes or the cholangiocytes where intracellular 
accumulation of toxic bile components occurs and harms the hepatocytes. This bile duct damage in turn 
leads to cholestasis, from which it can further lead to fibrosis, cirrhosis, or even liver failure [75, 76]. The 
incidence rate of these autoimmune liver diseases is about 1-2 per 100.000 individuals per year [77].  
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PBC was first called primary biliary cirrhosis, but cirrhosis did not reflect the natural pathogenesis of the 
disease, which is rather an endpoint [78]. About 15-25% of PBC patients progress to liver failure and require 
transplantation. PBC occurs in small and intermediate intrahepatic bile ducts, where immunopathological 
alterations and injury by hydrophobic bile acids cause structural damage, ductopenia, and peri-biliary 
stromal propagation [75, 79]. Most of the patients are asymptomatic and nowadays diagnosed through 
serum measurements of cholestasis markers such as elevated alkaline phosphatase (AP) and gamma-
glutamyl Transferase (γGT) serum levels, as well as anti-mitochondrial antibodies (AMA), since AMA is 
present in approx. 90% of all PBC patients and offers a 95% specificity in PBC [80]. Liver biopsy is no longer 
necessary to confirm the diagnosis of PBC. 
Primary sclerosing cholangitis (PSC) appears in intra- and extrahepatic bile ducts. Half of the patients are 
symptomatic and display symptoms such as pruritus, abdominal pain, and hyperbilirubinemia, and show 
signs such as hepatomegaly in about 44% of the cases. Along with this, the levels of alkaline phosphatase 
(AP), gamma-glutamyl Transferase (γGT), and transaminases (AST, ALT) in a patient’s serum can be 
elevated, although bilirubin levels are in the normal range in up to 70% of the patients. Early pathogenesis 
in PSC exists as a result of a peri-biliary inflammatory reaction and extinctive scars on the bile duct 
epithelium, which lead to atrophy, inflammation, or dilatation. Onion-like fibrosis is associated with 
progressive bile duct destruction [79, 81]. Unlike in PBC, further investigations such as cholangiography of 
the biliary tree or magnetic resonance cholangiopancreatography (MRCP) are essential to confirm the 
diagnosis and avoid biopsy.  
Ursodeoxycholic acid (UDCA) is the first-line treatment so far for both diseases. Normalization of the liver 
serum parameters such as alkaline phosphatase (AP) and gamma-glutamyl Transferase (γGT) can be 
achieved and disease symptoms such as pruritus and hyperbilirubinemia can be alleviated. UDCA is a 
physiological component of the human bile and its therapeutic effect under cholestatic conditions comes 
from stimulation of the impaired hydrophobic bile acid secretion. Due to the lack of understanding of PSC 
and PBC pathogenesis, no curative treatment is available yet apart from liver transplantation. Since up to 
40% of PBC patients do not respond to UDCA [82] and the use in PSC patients, where it can reach clinical 
endpoints if applied in high doses, is controversial [83], new therapy approaches are needed. Novel 
therapies are under evaluation and consider norursodeoxycholic acid (NorUDCA), which lacks a methylene 
group and facilitates passive transport into the cholangiocytes [84, 85]. Other approaches deal with 
nuclear receptor targeting such as the Farnesoid X receptor (FXR) or the peroxisome proliferator-activated 
receptor α (PPARα). Bile acids may serve as ligands for these nuclear hormone receptors, which are 
important in the expression regulation of hepatic transporters and bile secretion [75].  
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Studies by Voumvouraki et al. [86] investigated TGF-β serum levels in the blood of primary biliary cirrhosis 
(PBC) patients. While TGF-β2 was observed to be high in HCV-induced cirrhosis when compared to 
controls, it was not regulated in early or late PBC, indicating that its point of action is not systemic in the 
body. Not much information about TGF-β2 is known in PBC or PSC, but it was observed to be regulated in 
MDR2-deficient (Abcb4) mice. Here, TGF-β2 was strongly upregulated in mice with high disease activity 
[87]. MDR2-KO mice harbor reliably mimicking features of human cholestatic liver disease with various 
aspects of chronic portal inflammation, intrahepatic and extrahepatic fibrosis of bile ducts, making it a 
well-suited model for investigations of PBC and PSC [88-90].  
1.1.6 Aims of this thesis 
TGF-β deregulation is involved in the pathogenesis of several diseases, including cancer and fibrosis, making 
it an interesting druggable target. Our investigations focused on the role and druggability of TGF-β2 in 
CLD and the fact that TGF-β1 strategies have not yet led to any full therapeutic success in CLD. In detail, 
the following issues are investigated in this thesis:  
1 TGF-β2 abundance in fibrogenesis and liver cancer development. To address this 
aim, the TGF-β1 and TGF-β2 isoforms and, in part, TGF-β receptors were analyzed 
using quantitative real-time PCR and ELISA in main non-malignant liver cells, e.g., 
primary hepatic stellate cells and hepatocytes, and in the human-derived HSC cell 
line LX-2. 
2 In mouse models of liver regeneration, fibrosis upon CCl4 challenge and in the case 
of biliary damage – here bile duct ligation and MDR2-KO – TGF-β isoform 
expression was examined at different stages and correlated with typical markers.  
3 Eight human hepatocellular carcinoma (HCC)/hepatoblastoma cell lines and one 
animal model (TGFα/cMyc) were utilized to compare TGF-β1 and TGF-β2 
expression in liver cancer. 
4 Publically available microarray data using the Oncomine® database was searched 
in order to analyze TGF-β isoform expression in human HCC and cirrhosis 
collectives. 
5 The effects of TGF-β2 silencing mediated by a TGF-β2-specific antisense-
oligonucleotide were investigated in early biliary-derived liver damage using the 
MDR2-KO model on the molecular, cellular, and tissue level. 
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6 An analysis of TGF-β2 attenuation was performed in the context of the fibrotic and 
inflammatory niche. 
7 The relevance of TGF-β2 expression in the tissues of patients with PSC and PBC was 
examined. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals 
All general chemicals were purchased from Carl Roth GmbH, Karlsruhe, Germany, or from Sigma-Aldrich 
Co., St. Louis, MO, USA, unless otherwise stated, and were of the highest quality. 
Acetone       Merck, Darmstadt, Germany 
Acrylamide/Bis Solution, 37.5:1 (30% w/v)   Serva, Heidelberg, Germany 
Ammonium persulfate (APS)                                                                          Sigma Aldrich, St. Louis, MO, USA 
Chloroform                                                                                                             Sigma Aldrich, St. Louis, MO, USA 
Chloramine-T hydrate                                                                                        Sigma Aldrich, St. Louis, MO, USA 
(N-Chloro-p-toluenesulfonamide sodium salt hydrate) 
DAPI       Roth, Karlsruhe, Germany 
Desoxy nucleoside triphosphates (dNTPs)   Peqlab, Erlangen, Germany 
Diethyl pyrocarbonate (DEPC), 99%                           Sigma Aldrich, St. Louis, MO, USA 
Dimethyl sulfoxide (DMSO)                                           Sigma Aldrich, St. Louis, MO, USA 
Dithiothreitol (DTT)      Roche, Mannheim, Germany 
3,3 -diaminobenzidine tetrahydrochloride (DAB)                                  Sigma Aldrich, St. Louis, MO, USA 
DRAQ5 Cell Signaling Technology, Danvers, MA, 
USA 
ECL substrate (electrochemiluminescence)    Amersham, Freiburg, Germany 
Enzymes       Fermentas, St. Leon- Rot, Germany 
EDTA, disodium salt      Merck, Darmstadt, Germany 
Ethidium bromide      Sigma Aldrich, St. Louis, MO, USA 
Ethanol, absolute or denatured    Merck, Darmstadt, Germany 
Ehrlich Reagenz - 4-(Dimethyl-amino) benzaldehyde  Sigma Aldrich, St. Louis, MO, USA 
Fetal Calf Serum (FCS)     Invitrogen, Karlsruhe, Germany  
Fetal Bovine Serum (FBS)     Invitrogen, Karlsruhe, Germany 
Fluorescent mounting medium    Dako, Hamburg, Germany 
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GelRed       GeneOne, Ludwigshafen, Germany 
Glacial acetic acid      Merck, Darmstadt, Germany 
Glycerol       Sigma Aldrich, St. Louis, MO, USA 
Glycine       Merck, Darmstadt, Germany 
Hank's Balanced Salt Solution (HBSS)  Thermo Fisher Scientific, Waltham, MA, 
USA 
Hydrogen peroxide, solution 30%  
(w/w) in H2O      Sigma Aldrich, St. Louis, MO, USA 
Hydrochloric acid (HCl)     Merck, Darmstadt, Germany 
Isopropanol       Merck, Darmstadt, Germany 
Le-Agarose       Biozym Scientific, Hessisch Olden- 
        dorf, Germany 
Luminol (3-aminophtolhydrazide)    Sigma, Munich, Germany 
Mayer`s Haematoxylin     Sigma, Munich, Germany 
Methanol       Merck, Darmstadt, Germany 
β-Mercaptoethanol      Merck, Darmstadt, Germany 
MOPS, buffer grade      AppliChem, Darmstadt, Germany 
NaOH       Merck, Darmstadt, Germany 
Nonident P40      Roche, Mannheim, Germany 
O.C.T. Compound Tissue Tek     Sakura Finetek Staufen, Germany 
Paraformaldehyde      Sigma, Munich, Germany 
p-coumaric acid      Sigma, Munich, Germany 
Penicillin/ Streptomycin     Invitrogen, Karlsruhe, Germany 
Perchloric acid 60%      AppliChem, Darmstadt, Germany 
Picrid Acid solution 1.3%     Sigma, Munich, Germany 
Poly-D-Lysine (P6407)     Sigma, Taufkirchen, Germany 
Phosphate buffered saline (PBS)    Invitrogen, Karlsruhe, Germany 
Power SYBR Green PCR Mastermix   Thermo Fisher Scientific, Waltham, MA, 
USA 
Protease inhibitor cocktail     Sigma, Munich, Germany 
Phosphatase inhibitor cocktail    Roche, Mannheim, Germany 
Roti®-Histofix 4 %      Carl Roth, Karlsruhe, Germany 
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Rat tail collagen I      Roche, Mannheim, Germany 
SDS , Sodium dodecylsulfate     Carl Roth, Karlsruhe, Germany 
Sirius Red       Sigma-Aldrich, St. Louis, MO, USA 
Sodium chloride (NaCl)     Carl Roth, Karlsruhe, Germany 
TaqMan Universal PCR Mix, no AmpErase UNG   Thermo Fisher Scientific, Waltham,
        MA, USA 
TEMED (N,N,N’,N’-Tetramethylethylene-diamine)  Sigma-Aldrich, St. Louis, MO, USA 
Transfer buffer solution 10x     Invitrogen, Karlsruhe, Germany 
trans-4-Hydroxy-L-proline     Sigma-Aldrich, St. Louis, MO, USA 
Tris, Tris(hydroximethyl)aminomethane   Carl Roth, Karlsruhe, Germany 
Triton X-100      Sigma-Aldrich, St. Louis, MO, USA 
TRizol       Invitrogen, Karlsruhe, Germany 
Trypsin       Sigma-Aldrich, St. Louis, MO, USA 
Trypanblue       Sigma-Aldrich, St. Louis, MO, USA 
Tween-20       Carl Roth, Karlsruhe, Germany 
 
2.1.2 Instruments 
Agilent 2100 Bioanalyzer     Agilent Technologies, Santa Clara, 
        CA, USA 
autoMACS® Pro Separator     Milteny Biotec, Bergisch Gladbach, 
        Germany 
autoMACS® Columns     Milteny Biotec, Bergisch Gladbach, 
        Germany 
Cell culture incubator, HERA cell    Kendro Laboratory, Hanau, Germany 
Chamber slides 8 wells     Becton Dickinson, Franklin Lakes, NJ,  
        USA 
Confocal microscope TCS SP8y    Leica, Wetzlar, Germany 
Cryostat CM 3050S      Leica, Wetzlar, Germany 
Dako Pen       Dako, Hamburg, Germany 
Fusion SL Imaging system     Peqlab, Erlangen, Germany 
Immobilon-P Transfer Membrane (PVDF)   Merck Millipore, Darmstadt, Germany 
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Intas Gel ix Imager      Intas, Göttingen, Germany 
Inverted light-microscope, Leica DMi8    Leica Biosystems, Wetzlar, Germany 
Laminar flow hood, HA 2472 GS    Heraeus Holding, Solingen, Germany 
PeqStar Universal 96 well PCR cycler    Peqlab, Erlangen, Germany 
PeqStar 48 well PCR cycler     Peqlab, Erlangen, Germany 
PRECELLYS®EVOLUTION homogenizer   Peqlab, Erlangen, Germany 
Realtime Stratagene MX 3005P    Agilent Technologies, Santa Clara, CA, 
        USA 
StepOne Plus Realtime PCR System  Thermo Fisher Scientific, Waltham, MA, 
USA 
StepOne realtime PCR     Agilent Technologies, Santa Clara, CA, 
        USA 
Tecan infinite M200 mit Nano-Quant    Tecan,  Männedorf, Germayn 
Upright light-microscope, LAS X Widefield Systems  Leica Biosystems, Wetzlar, Germany 
2.2 Cell Culture 
2.2.1 Cell culture reagents and additives 
William’s E medium      Invitrogen, Karlsruhe, Germany 
Dulbecco’s Modified Eagle’s Medium (DMEM)  
with 25nM Hepes, 4.5g glucose    Lonza, Basel, Switzerland 
Dulbecco’s Modified Eagle’s Medium (DMEM) 
without phenol red      Lonza, Basel, Switzerland 
RPMI 1640 medium      Lonza, Basel, Switzerland 
L-Glutamine      PAA, Cölbe, Germany 
Fetal bovine serum (FBS)     Invitrogen, Karlsruhe, Germany 
Hank’s Buffered Salt Solution (HBSS)    PAA, Cölbe, Germany 
10x Trypsin (2.5% in PBS w/o calcium and magnesium  PAA, Cölbe, Germany 
Dexamethasone      Sigma-Aldrich, St. Louis, MO, USA 
Penicillin/Streptomycin     Lonza, Basel, Switzerland 
Human recombinant TGF-β1     Peprotech, Hamburg, Germany 
Human recombinant TGF-β2     Peprotech, Hamburg, Germany 
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2.2.2 Cell lines 
Name Description Culture medium Literature 
HLE and HLF HCC cell line derived from 
68-year-old patient, 
poorly differentiated 
DMEM supplemented 
with 10% FBS, 2 mM glu-
tamine, 100 units/ml of 
penicillin, and 50 μg/ml 
of streptomycin 
[91] 
HuH7 Derived from liver tumor 
of 57-year-old Japanese 
male in 1982, HBV/HCV 
negative 
DMEM supplemented 
with 10% FBS, 2 mM glu-
tamine, 100 units/ml of 
penicillin, and 50 μg/ml 
of streptomycin 
[92] 
HuH6 Derived from human liver 
hepatoblastoma of Japa-
nese infant, epithelial-like, 
HBV/HCV negative 
RPMI 1640 medium sup-
plemented with 10% 
FBS, 2 mM glutamine, 
100 units/ml of penicillin, 
and 50 μg/ml of strepto-
mycin 
[92] 
Hep3B Differentiated human liver 
carcinoma-derived cell 
line from 8-year-old black 
American, tumor for-
mation when injected into 
nude mice, HBV/HCV pos-
itive 
DMEM supplemented 
with 10% FBS, 2 mM glu-
tamine, 100 units/ml of 
penicillin, and 50 μg/ml 
of streptomycin 
[93, 94] 
HepG2 Derived from liver biopsy 
of 15-year-old male Cau-
casian, well differentiated 
HCC, epithelial, HBV/HCV 
negative 
DMEM supplemented 
with 10% FBS, 2 mM glu-
tamine, 100 units/ml of 
penicillin, and 50 μg/ml 
of streptomycin 
[94] 
FLC-4 Mutant of HCC cell line 
JHH-4, which was estab-
lished from 51-year-old 
Japanese male with HCC 
of Edmondson’s type III, 
well differentiated, 
HBV/HCV positive 
DMEM supplemented 
with 10% FBS, 2 mM glu-
tamine, 100 units/ml of 
penicillin, and 50 μg/ml 
of streptomycin 
[95] 
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PLC/PRF/5 
(Alexander) 
Derived from a 24-year-
old male patient from 
Mozambique, HCV posi-
tive, cirrhotic 
DMEM supplemented 
with 10% FBS, 2 mM glu-
tamine, 100 units/ml of 
penicillin, and 50 μg/ml 
of streptomycin 
[93, 96] 
LX-2 (Lieming 
Xu) 
Human stellate cells, de-
rived from colla-
genase/pronase perfusion 
of normal liver tissue, then 
spontaneously immortal-
ized in low serum condi-
tions LX-1  
DMEM supplemented 
with 2% FBS, 2 mM glu-
tamine, 100 units/ml of 
penicillin, and 50 μg/ml 
of streptomycin 
[97] 
Table 1 Cell lines 
2.2.3 Cell culture and treatment 
Human hepatocellular cancer cell lines HepG2, Hep3B, PLC/PRF, HLE, HLF, FLC-4, and HuH7, and the human 
HSC cell line Lieming Xu (LX)-2 were cultured in Dulbecco’s modified Eagle’s medium (Lonza, Basel) with 
10% fetal bovine serum for HCC cell lines, respectively 2% for LX-2 cells, 1% penicillin (100 
IU/ml)/streptomycin (100 μg/ml), and 2 mM glutamine. Human hepatoblastoma cell line HuH6 cells were 
cultured in RPMI 1640 medium (Lonza, Basel) with 10% fetal bovine serum, 1% P/S, and 1% glutamine. The 
cells were maintained in a 37°C humidified atmosphere containing 5% CO2. 
24 hours prior to the HCC cell line and the HSC line experiments, the medium was changed to ‘starvation 
medium’ with 0.5% FBS, and either 5 ng/ml or 10 ng/ml TGF-β (PeproTech GmbH, Hamburg) were used as 
indicated in the figures. For long-term storage, the cells were trypsinized and harvested through the 
addition of medium. Next, the cells were centrifuged, re-suspended in FCS containing 10% DMSO, and 
transferred as 1 ml aliquots into cryovials. The cells were stored at -80°C or in liquid nitrogen. To thaw the 
cells, the cryovials were kept for several minutes at 37°C and mixed with fresh medium to remove DMSO. 
After centrifugation for 3 minutes at 1000 rpm, the cells were re-suspended with new medium and re-
plated in a petri dish. 
Routinely, all cells were screened for mycoplasma contamination using the PCR Mycoplasma Test Kit I/C from 
PromoKine following the manufacturer’s protocol. 
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2.2.4 TGF-β2 inhibition using antisense oligonucleotides (AONs) 
Human LX-2, HuH7 cells were cultured at medium density to perform AON experiments. AON or scrambled 
oligonucleotide transfection was performed using RNAiMAX (Invitrogen, Darmstadt) according to the 
manufacturer’s protocol. Briefly, the oligonucleotide and RNAiMAX were diluted in Opti-MEM (Life 
Technologies) and equal volumes were added to each other in a separate tube and then incubated for 20 
min at room temperature. Subsequently, the DNA/RNAiMax solution was added dropwise to the medium, 
which was replaced after 6 hours of incubation. Knockdown efficiency was verified by quantitative real-
time PCR. Two different AON and scrambled control concentrations were applied (1 nmol and 20 nmol). 
Knockdown was allowed to establish for 48h in medium supplemented with either 2% FBS for LX-2 or 10% 
FBS for HuH7. The TGF-β2 inhibition oligonucleotides (ASP_0047 and C3_0047) were provided by Isarna 
Therapeutics. 
2.2.5 Primary murine hepatocyte isolation and culture 
Primary hepatocytes were isolated from the livers of male C57BL/6 wild-type mice by collagenase perfusion 
[98]. The animals were handled and housed according to specific pathogen-free (SPF) conditions. 
Anesthesia was applied by intraperitoneal injection of a Ketamine/ Xylazine hydrochloride mixture. Liver 
perfusion was followed by liver removal and transfer to a petri dish in a sterile hood. Suspension of single 
cells was achieved by removal of the liver capsule and gentle shaking. The suspension was placed on a cell 
strainer (100 µm) and filtered through the mesh by gravity flow. After two further wash steps, the cells 
were centrifuged and then re-suspended in Williams E medium. Cell viability was determined by counting 
of Trypan blue-stained and unstained cells. The cells were plated on collagen-I-coated plates and cultured 
in Williams E medium supplemented with 10% fetal bovine serum, 1% penicillin (100 IU/ml)/streptomycin 
(100 μg/ml), 2 mM glutamine, and 0.1% Dexamethasone. After 4 hours of attachment, the cells were 
overlayed with Williams E medium for monolayer cultures or with collagen and medium for sandwich 
cultures. Collagen sandwich cultures were established as described in [99]. 
2.2.6 Isolation of primary mouse HSCs 
Primary HSCs were isolated from female BALB/c wild-type mice by pronase/collagenase digestion followed 
by density gradient centrifugation and were cultured on plastic dishes in DMEM, supplemented with 4 mM 
L-glutamine, 10% FBS, and penicillin (100 IU/ml)/streptomycin (100 μg/ml) as described in [100]. The mice 
were anesthetized with an intraperitoneal injection of a Ketamine/ Xylazine hydrochloride mixture. The 
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livers were perfused through the inferior vena cava interior with EGTA solution (Sigma-Aldrich), followed 
by Pronase E solution (Sigma-Aldrich) and finally Collagenase D (Biochrom, Merk Millipore) solution. The 
livers were removed, placed into ice-cold DMEM, and the liver capsule was opened to obtain single cells. 
Cell debris and hepatocytes were removed through several wash and centrifugation steps. To separate 
stellate cells from the cell suspension, density gradient centrifugation was performed. In the resulting 
layers, stellate cells were located in the thin white layer below the clear HBSS solution. Then the cells were 
collected and, following two further wash steps, cell viability was determined by counting with Trypan blue 
and purity was assessed with UV light.  
2.2.7 Simultaneous isolation of four liver cell types based on magnetic bead separation 
Primary liver cells were isolated from BALB/c wild-type mice by collagenase perfusion followed by liver tissue 
separation with the autoMACS® Pro Separator (Milteny) and then cell-type-specific magnetic beads 
(Microbeads, Milteny). The mice were anesthetized with an intraperitoneal injection of a Ketamine/ 
Xylazine hydrochloride mixture. Liver perfusion started with insertion into the vena cava interior followed 
by a flow-through with EGTA solution and then Collagenase D solution. The liver was removed and placed 
in the autoMACS® Pro Separator (Milteny) for tissue dissociation. Hepatocyte separation was done before 
using low-speed centrifugation and later purification by Percoll (VWR). The single-cell suspension was then 
labeled with cell-type-specific MicroBeads for a certain incubation period (~15-30 min). The labeled cell 
suspension was then transferred to a MACS Column and placed in the MACS Separator, which induced a 
magnetic field and created a high gradient in the column. While positive-labeled cells were retained in the 
magnetic field, unlabeled cells passed through the column (negative fraction). This negative fraction was 
then used for the next cell-type-specific MicroBead labeling. These steps were performed until all cell-
type-specific microbeads had been applied to the cell suspension. After the cells had been collected, and 
following further wash steps, cell viability was determined by counting with Trypan blue and purity was 
assessed either by immunofluorescence or qPCR. The following beads were used: for Kupfer cells (CD11b, 
Milteny), for LSEC (CD146, Milteny), and for stellate cells CD271 (Milteny). 
2.3 Protein Biochemistry Methods 
2.3.1 Cell lysates 
Adherent cells were grown to confluency and then washed with PBS on ice. To lyse the cells, a RIPA buffer 
containing phosphatase and protease inhibitors was added and incubated for 10 to 20 minutes on ice. The 
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cells were then removed from the dish by scraping using a cell scraper, transferred to a collection tube, and 
spun down to remove cell debris (10 mins, 10000 rpm, 4 °C). 
For tissue homogenization of the mouse livers, small liver pieces were placed in a 500 µl complete RIPA 
buffer in the provided tubes containing a mix of 1.4 mm & 2.8 mm ceramic beads, and followed by 
homogenization with the PRECELLYS®EVOLUTION homogenizer at 5000 rpm for 40 s. The samples were 
then placed on ice and incubated for 30 min, centrifuged at 10.000 rpm for 5 min, and then transferred into 
a new tube to remove the ceramic beads. With a second centrifugation step, cell debris was removed from 
the solution and the proteins were ready for further use. 
The protein concentration was determined by performing the Lowry method (2.3.2) and then used directly 
for SDS-PAGE gel electrophoresis or stored at -20 °C. 
2.3.2 Lowry method for determination of protein concentration  
Protein concentration was determined by using a BCA protein assay (Pierce, Thermo Scientific) based on 
the Lowry method. For this purpose, 1 µl of protein sample or BSA standard (0-10 mg/ml) were transferred 
to a microtiter plate and supplemented with a 20 µl mix of solutions A and S (Pierce, Thermo Scientific). 
Each sample was then mixed with 200 μl of solution B and incubated for 15 min at room temperature on 
the shaker. Immediately, the absorption of all samples was detected at 690 nm using a microplate reader. 
Protein concentrations were calculated according to the BSA standard curve. 
2.3.3 Protein sample preparation for SDS-PAGE 
Equal amounts of protein (10-20 µg) were mixed with 4x loading buffer NuPAGE LDS Sample Buffer 
(Invitrogen) and 1 µl DTT (1M) and incubated at 95 °C for 5 min. The lysates were then briefly centrifuged 
and placed on ice, making them ready for SDS-PAGE gel protein separation (2.3.4). 
2.3.4 SDS-PAGE gel protein separation 
The proteins were separated electrophoretically on the basis of size as described in Laemmli [101]. Precasted 
NuPAGE 4-12 % Bis-Tris gel (1.5 mm x 15 wells) (Invitrogen) and an MOPS buffer were used as the standard 
protocol and electrophoresis was performed in an XCell II Mini Cell chamber (Invitrogen) for about 1 hour 
at a constant voltage of 150 V. Self-made gels were prepared (10-12 %) and ran in the Bio-Rad system for 
1.5 hours at a constant voltage of 100 V in a Laemmli buffer. 
Running gel: 7% Acrylamid; 0.375 M Tris pH 8.8; 0.1% SDS; 0.1% APS; 0.01% Temed 
Stacking gel: 3% Acrylamid; 0.125 M Tris pH 6.8; 0.1% SDS; 0.1% APS; 0.01% Temed 
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Laemmli buffer: 25 mM Tris pH 8.3; 192 mM Glycin; 0.1% SDS 
After the proteins had been separated by SDS-PAGE, they were electrically transferred onto a nitrocellulose 
membrane (0.45 micron, Pierce) encased by chromatography papers (3MM, Whatman) (sandwich blot) 
placed in an XCell II Blot module at 300 mA for 2-3 hours on ice. When the membrane transfer procedure 
was completed, the membrane was incubated with Ponceau Red solution to determine equal protein 
loading and to reduce unspecific binding of antibodies, then incubated with a blocking buffer at room 
temperature for 1 hour upon gentle shaking. Afterwards, the membrane was incubated with an 
appropriate primary antibody (following the manufacturer´s recommendations) at 4 °C overnight. After 
three washes in TBST buffer, the membrane was incubated with an HRP-conjugated secondary antibody 
in a 1:1000 dilution for 1 hour at room temperature and re-washed with TBST buffer. Finally, specific 
proteins were detected by enhanced chemiluminescence using ECL Western blotting detection reagents 
(SuperSignal West Dura, Pierce) following the manufacturer´s instructions. Chemiluminescence was 
detected using the Fusion SL Imaging system (Peqlab). The antibodies are listed in Table 2. 
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Antibodies used for Westernblot (WB) and Immunostaining (IHC) / 
Immunofluorescence (IF) 
Epitope Species Company Cat No. Dilution 
pSmad3/1 rabbit Abcam (formerly 
Epitomics) 
1880-1 1:1000 (WB) 
1:500 (IF) 
pSmad2 rabbit Cell signaling 3101 1:1000 (WB) 
1:250 (IF) 
GAPDH rabbit Santa Cruz sc-25778 1:1000 (WB) 
Smad2/3 rabbit Cell Signaling 3102 1:1000 (WB) 
Smad1 rabbit Cell Signaling 9743 1:1000 (WB) 
Digoxigenin goat Abcam ab76907 1:300 (IF,IHC) 
pp38 rabbit Cell Signaling 9215 1:1000 (WB) 
p38 rabbit Cell Signaling 9212 1:1000 (WB) 
Desmin rabbit Abcam ab15200 1:200 (IF) 
Alpha Smooth mus-
cle actin 
rabbit Abcam ab5694 1:200 (IF) 
1:500 (IHC) 
CD31 rabbit Abcam ab28364 1:200 (IF) 
F4/80 rat eBioscience 14-4801-
85 
1:200 (IF) 
TGF-β2  Abcam ab36495 1:1000 (IHC) 
Goat anti-rabbit 
IgG-HRP 
goat Santa Cruz sc-2301 1:10.000 
Goat anti-mouse 
IgG-HRP 
goat Santa Cruz sc-2005 1:10.000 
Alexa 546 goat-anti-
rat 
rat 
Invitrogen A11081 1:200 (IF) 
Alexa 488 goat-anti-
mouse  
mouse Invitrogen A11029 1:200 (IF) 
Alexa 488 goat-anti-
rabbit 
rabbit Invitrogen A11008 1:200 (IF) 
Alexa 555 goat-anti-
rabbit 
rabbit Invitrogen A21428 1:200 (IF) 
Alexa 555 rabbit-
anti-goat 
goat Invitrogen A21431 1:200 (IF) 
TO-PRO®-3 nucleic 
dye 
Thermo Fisher Sci-
entific  
T3605 1:1000 (IF) 
Table 2 Primary and secondary antibodies used for immunoblot, immunohistochemical, and immunofluorescence 
analysis 
2.4 Enzyme-Linked Immunosorbent Assays (ELISA) 
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For the determination of secreted TGF-β1 and TGF-β2 in cell supernatants or lysates following conventional 
cell culture, ELISA was performed. For cell lysates, the cell culture medium was removed by centrifugation, 
Cell Lysis Buffer 1 (R & D Systems, Minneapolis) was added to the cell pellet, and the mixture was allowed 
to incubate for 60 minutes with gentle agitation. After activating TGF-β through acidification in the 
collected supernatants or lysates, ELISA was performed according to the manufacturer’s instructions for 
Quantikine human TGF-β1 or murine TGF-β1 (R & D Systems, Minneapolis), respectively for Quantikine 
human TGF-β2 or murine TGF-β2 (R & D Systems, Minneapolis). Measurement of TGF-β1 and TGF-β2 
secretion of murine HSCs was performed using the ELISA-based system Luminex (BioRad, Munich). 
2.5 DNA and RNA Methods 
2.5.1 RNA isolation and reverse transcription 
The total RNA was extracted from cells or tissue according to the manufacturer’s instructions using either 
the InviTrap Spin Universal RNA Mini Kit (Stratec, Birkenfeld) or the TRizol reagent (Invitrogen, Karlsruhe), 
with subsequent chloroform extraction as described in [102]. The RNA concentration was determined with 
the help of the Tecan infinite M200 Microplate reader (Tecan, Switzerland). Reverse transcription to cDNA 
was performed with cDNA synthesis reagents (Thermo Scientific). cDNA was synthesized using 0.5–1 μg 
of the total RNA. For quantitative real-time PCR or conventional PCR, the samples were diluted with 
ddH2O at a ratio of 1:5 to 1:10.  
2.5.2 Polymerase Chain Reaction (PCR) 
To amplify specific DNA fragments, PCR was performed using the Taq DNA Polymerase and dNTPack 
system (Roche, Mannheim). In order to separate DNA fragments according to their size, a 1-2% agarose 
gel with 1xTAE buffer was prepared. GelRed (GeneOn, Ludwigshafen) or Ethidiumbromide was added to 
visualize the DNA on a UV transilluminator. The primers are listed in Table 4. 
TAE buffer: 40 mM Tris Base; 20 mM glacial acidic acid; 1 mM EDTA pH 8.0 
2.5.3 Quantitative real-time PCR 
Real-time polymerase chain reaction (qPCR) was carried out with Power SYBR Green (Life Technologies) or 
TaqMan Universal Master Mix II (Life Technologies) using the Stratagene MX 3005 P or StepOne Plus 
Realtime PCR system. Gene expression was analyzed using 2 µl of each diluted sample and a mix 
containing 10 μl of SYBRGreen (2x), 1μl of forward and reverse primer (10µM), and 6 μl of ddH2O in a total 
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volume of 20 μl. For the performance with TaqMan probes, only 1 µl of probe was used. After 
centrifugation, qPCR was started and the samples were amplified with the following program: 40 cycles 
from step 2 to 4. 
1) 95 °C – 10 min, 2) 95 °C – 15 sec, 3) 60 °C – 1 min, 4) 72 °C – 1 min 
Each sample was analyzed either in duplicates or triplicates and evaluated as follows. The threshold of 
fluorescence above the background of fluorescence was defined as the point at which the fluorescence 
increases significantly and was measured by the real-time qPCR device. The results were displayed as the 
CT values at which the fluorescence of a sample crossed the threshold. The relative quantity of target 
genes was determined according to the ΔΔCt (“delta-delta”) method [103]. To compensate for the 
variation between qPCR runs, the target gene expression was normalized to the expression of the 
endogenous, unregulated reference gene rS18, HPRT, or PPIA. To ensure that the primers produced 
specific PCR amplification products, a dissociation curve was analyzed to guarantee specificity. (Only 
primers with a unique dissociation peak were used).The primers and probes are listed in Table 3 and Table 
4, respectively.  
 
R – relative ratio 
Ct – deviation of Ct values 
[104] – gene whose relative expression ratio between control and sample is measured 
Gene Name Assay ID Species qPCR Type 
Endoglin HS00923996_m1 human Taqman  
TGF-βRI HS00610320_m1 human Taqman 
TGF-βRII HS00947893_m1 human Taqman 
TGF-βRIII Hs01114253_m1 human Taqman 
rS18 Hs03003631_g1 human  Taqman 
TGF-β2 Mm00436955_m1 mouse Taqman 
TGF-β1 Mm01178820_m1 mouse Taqman 
PPIA Mm02342430_g1 mouse Taqman 
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Table 3 qPCR primer sets based on Taqman assays. 
Gene 
Name 
Forward Reverse Spe-
cies 
rS18  AAACGGCTACCACATCCAAG CCTCCAATGGATCCTCGTTA human 
HPRT CCTGGCGTCGTGATTAGTGA CGAGCAAGACGTTCAGTCCT human 
TGF-β1 TGGTGGAAACCCACAACGAA GAGCAACACGGGTTCAGGA human 
TGF-β2 GCAGATCCTGAGCAAGCTG GTAGGGTCTGTAGAAAGTGG human 
PCNA CTGAGGGCTTCGACACCTAC TCACTCCGTCTTTTGCACAG human 
CD45 CCCCGGACTCTTTGGATAAT AGGGTTGAGTTTTGCATTGG human 
PPARg GTGGCCGCAGAAATGACC CCACGGAGCTGATCCCAA human 
    
Ppia GAGCTGTTTGCAGACAAAGTC CCCTGGCACATGAATCCTGG mouse 
TgfB1 AGGGCTACCATGCCAACTTC CCACGTAGTAGACGATGGC mouse 
TgfB2 GCAGATCCTGAGCAAGCTG GTAGGGTCTGTAGAAAGTGG mouse 
Col1a1 ACGTGGAAACCCGAGGTATG TTGGGTCCCTCGACTCCTAC mouse 
Col3a1 ACGTAAGCACTGGTGGACAG GGAGGGCCATAGCTGAACTG mouse 
smaA TTCGCTGTCTACCTTCCAGC GAGGCGCTGATCCACAAAAC mouse 
PparG TCCAGCATTTCTGCTCCACA ACAGACTCGGCACTCAATGG mouse 
TnfA CCCTCACACTCACAAACCAC ATAGCAAATCGGCTGACGGT mouse 
Timp1 CGAGACCACCTTATACCAGCG ATGACTGGGGTGTAGGCGTA mouse 
Il-6 TAGTCCTTCCTACCCCAATTTCC TTGGTCCTTAGCCACTCCTTC mouse 
Il-1B CCCAACTGGTACATCAGCACCTC GACACGGATTCCATGGTGAAGTC mouse 
Ctgf AGATTGGAGTGTGCACTGCCAAAG TCCAGGCAAGTGCATTGGTATTTG mouse 
Muc CCAAGCGTAGCCCCTATGAG GTGGGGTGACTTGCTCCTAC mouse 
Tff2 CTTGGTGTTTCCACCCACTT CACCAGGGCACTTCAAAGA mouse 
Cd45 TGTACCACCAGGGACTGACAAG TCTGGCTCACAGTGGAGTACATATG mouse 
Table 4 qPCR primer sets based on the SybrGreen approach. 
2.6 Immunohistochemistry (IHC) and Immunofluorescence (IF) 
2.6.1 Immunofluorescence 
2.6.1.1 Cryosections of liver tissue 
After liver resection, a fresh part of the right liver lobe was placed in a cryomold, embedded in Tissue-Tek® 
O.C.T. (Sakura, Germany), and gently frozen on dry ice. The frozen blocks were cut into 5 μm sections with 
the Cryostat CM 3050S (Leica) and were dried overnight at room temperature. The sections were stored 
for direct use at -20 °C or for future use at -80 °C. 
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2.6.1.2 Immunofluorescence staining 
The slides were fixed either with cold 4% paraformaldehyde or ice-cold acetone at room temperature for 10 
minutes. The tissue was rinsed in PBS pH 7.0 and surrounded with a hydrophobic barrier using a barrier pen 
(DAKO). The specimens were blocked and permeabilized for 60 minutes with a blocking buffer containing 
0.3% Triton X-100. Afterwards, a primary antibody solution was applied to each slide according to the 
manufacturer’s recommendations and incubated at 4 °C overnight in the dark. The next day, the sections 
were washed three times with PBS pH 8.0 and an appropriate secondary antibody was applied and 
incubated for 1-2 hours at room temperature. For nuclear counterstaining, TO-PRO®-3 (dilution 1:1.000 in 
PBS) was added to the slides for 15 minutes. The sections were then washed three times in PBS, mounted 
with aqueous Fluorescent Mounting Medium (S3023, Dako), and examined with a confocal microscope 
(TCS SP8y, Leica). As negative controls, sections were incubated with secondary antibodies only. 
2.6.2 Immunohistochemistry (IHC) 
2.6.2.1 Paraffin sections  
The tissues were fixed with Roti®-Histofix 4 % (Roth) or other fixatives for 24-48 hours at room temperature. 
The fixed tissues were placed in embedding cassettes and processed for paraffin embedding as follows: 
 70% ethanol, two changes, 1 hour each 
 80% ethanol, one change, 1 hour 
95% ethanol, one change, 1 hour 
 
100% ethanol, three changes, 1.5 hour each 
 
Xylene, three changes, 1.5 hour each and then  
 
paraffin wax (58-60 ºC), two changes, 2 hours each. 
 
Paraffin blocks were then used to generate 4-6 µm tissue sections. These sections were dried ei-
ther overnight at 37 °C or for 1 hour at 60 °C. 
 
2.6.2.2 Immunohistochemical staining 
Immunohistochemical staining was performed using sections of 4-6 μm thickness and were de-paraffinized 
in xylene, and rehydrated in decreasing concentrations of alcohol. Antigen retrieval was achieved in either 
EDTA buffer (1mM, pH 8.0) or Tris-NaCitrate-Dihydrate buffer (0.01M, pH 6) by microwave treatment. To 
block endogenous peroxidase activity, the slides were treated with 10% H2O2 for 15 min at room 
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temperature followed by incubation with the primary antibody (see Table 2) at 4 °C overnight. After rinsing 
with PBS, the sections were incubated with horseradish peroxidase conjugated secondary antibody for 30-
45 min and visualized with 3,3-diaminobenzidine tetrahydrochloride (DAB) (D5905, Sigma) staining. The 
samples were then counterstained with hematoxylin and examined under a light microscope. 
2.6.2.3 Picro Sirius Red staining and quantification  
For the detection of collagen, the paraffin sections were de-waxed and hydrated and the nuclei were stained 
with hematoxylin for 8 min. The slides were washed under running tap water for 10 min and then stained 
with Picro Sirius Red solution (Sigma) for 1 hour at room temperature. In two changes, the samples were 
washed with acidified water (0.5% acetic acid), dehydrated with ethanol, and cleared in xylene [105, 106]. 
The quantification of Picro Sirius Red staining was achieved from nine non-overlapping 10x magnified 
fields of each liver sample and displayed in percentages of the total liver area using the software ImageJ 
1.49v. Regions of large centrilobular veins and large portal tracts were excluded from the calculation. 
2.7 Hydroxyproline Assay 
Liver collagen content was quantified colorimetrically as total hydroxyproline as described in [107, 108]. One 
snap frozen liver specimen from the caudate lobe, weighing between 50 and 100 mg, was incubated in 2 
ml of 6N HCl (Sigma) for 30 min at 110 °C, then briefly homogenized , followed by a 16 h hydrolysis at 110 
°C. The solution was then filtered to remove solids and the supernatant was collected. Triplicates of 15 
microliters of the supernatant were placed into Eppendorf tubes and mixed with 15 µl of methanol, then 
dried at 75-80 °C; the resulting crystals were dissolved in 0.5 ml 50% isopropanol. In the next step, 100 µl 
of Chloramine-T solution was added and incubated for 10 min. Then 0.5 ml of freshly prepared Ehrlich´s 
reagent was added to the reaction mixture and incubated at 50 °C for 90 min. Absorbance was measured 
at 558 nm in a Tecan infinite M200 Microplate reader (Tecan, Switzerland). Total hydroxyproline (µg/liver 
weight) was calculated on the basis of the individual liver weights, the corresponding relative 
hydroxyproline content, and the liver lysate dilution factors. 
2.8 Animal Models for Liver Fibrosis and Carcinogenesis  
2.8.1 Mice and animal husbandry 
Wild-type mice were obtained from Charles River or Jackson Laboratory and MDR2-KO (Mdr2−/−) mice were 
kindly provided by F. Lammert, Saarland University Medical Center. The animals were housed under 
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specific-pathogen–free conditions in the animal facility of the Medical Faculty Mannheim, Heidelberg 
University. They received human care and all animal protocols were in full compliance with the guidelines 
for animal care and approved by the government’s Animal Care Committee. For all experiments, the mice 
were between 10 and 20 weeks old. Genotyping of all transgenic mice was performed by conventional PCR.  
2.8.2 Plasma liver function parameter analysis 
Whole blood was obtained via retrobulbar blood draw from the mice. The blood samples were collected in 
Lithium-Heparin microvettes, incubated for 5 min at room temperature on a roll shaker, and then 
centrifuged at 2.000×g for 5 min at 4 °C. Supernatant (plasma) was transferred to a new Eppendorf tube 
and either stored at −80 °C or used directly for analysis. The plasma concentrations of alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AP), glucose, 
cholesterol, triglycerides, proteins, bilirubin, and glutamate dehydrogenase (GLDH) activities were 
measured with the Cobas® 8000 analyzer (Roche, Mannheim).  
2.8.3 Biodistribution of a labeled antisense oligonucleotide (AON) in vivo 
Sixteen-week-old Balb/c wild-type mice were injected either intraperitoneally (i.p.) or subcutaneously (s.c.) 
with a single dose of 10 mg/kg of body weight FAM-labeled AON (ASP_0047). The hepatotropic efficiency 
of the application method and the AON content in the liver were decisive for the choice of the application 
method. 24 h and 5 days after AON administration, the mice were sacrificed; blood was taken, and liver, 
spleen, kidney, and lungs were resected. The FAM-labeled AON (ASP_0047) content was then determined 
in cryosections using a confocal microscope (2.6.1.1). 
After the precondition definition of the AON application, the AON biodistribution was determined in two 
mouse models of chronic liver diseases. In a model for biliary fibrosis, MDR2-KO mice were subcutaneously 
(s.c.) injected with a single dose of 10 mg/kg of body weight Digoxigenin-labeled AON (ASP_0047). All 
mice were sacrificed 72 h after AON administration and liver samples were immediately snap-frozen in 
liquid nitrogen according to standard operating procedures. Specimen sampling was performed for RNA, 
protein, plasma, and immunohistochemical analyses. Female and male mice were included in order to 
observe any gender-specific differences. 
2.8.4 Acute and chronic CCl4-induced liver damage 
In eight-week-old C57BL/6 mice (4 animals per group), acute liver damage was induced by a single 
intraperitoneal injection of 1 ml/kg per body weight CCl4 (mixed 1:8 with mineral oil). At 0 h, 3 h, 6 h, day 
 33 
1, day 2, day 3, or day 6 post injection, the mice were sacrificed and liver and blood specimens were 
obtained according to standard operating procedures.  
Chronic liver damage mRNA samples were kindly provided by S. Weber (Homburg). C57BL/6 or Balb/c mice 
received intraperitoneal injections of CCl4 (0.7 ml/kg per body weight in mineral oil) twice a week for six 
weeks.  Liver samples were taken from untreated mice, 24 h after a single CCl4 injection, after three CCl4 
injections, and after 6 weeks of two CCl4 injections per week (nut = 12; n24h = 12; n3x = 13; n6wk = 12 animals 
per group). Untreated animals or animals treated with mineral oil served as controls for the gene 
expression analysis.  
2.8.5 MDR2-KO – a model for cholestatic fibrosis 
RNA samples of age-matched male MDR2-KO (Mdr2−/−) and control C57BL/6 wild-type mice were kindly 
provided by P. Angel and J. Hess (Heidelberg). The mice were sacrificed at the age of 3, 6, 9, and 15 months 
and liver and blood samples were obtained according to standard operating procedures. RNA samples 
were used for gene expression analysis (Fluidigm). 
2.8.6 Systemic AON treatment in MDR2-KO mice 
14-week-old sex-matched Mdr2-/- mice (MDR2-KO) and control Balb/c wild-type animals received in the first 
week either 15ml/kg of body weight C3_0047 (control oligo) or ASP_0047 (AON) every day for five 
consecutive days (oligo push). The following treatment was then applied once per week for another three 
weeks. Six groups of animals were included as follows:  
 Balb/c untreated group (n=6, untreated for 4 weeks);  
 Balb/c control group (n=10, received 15ml/kg of body weight of C3_0047 (control oligo));  
 Balb/c AON group (n=10, received 15ml/kg of body weight of ASP_0047 (AON));  
 MDR2-KO control group (n=10, untreated for 4 weeks);  
 MDR2-KO control oligo group (n=10, received 15ml/kg of body weight of C3_0047 (control oligo)); and  
MDR2-KO AON group (n=9, received 15ml/kg of body weight of ASP_0047 (AON)).  
The mice were sacrificed 72 h after the last treatment and specimens were sampled according to standard 
operating procedures for further analysis. The study design is displayed in Figure 5.  
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2.8.7 Bile duct– ligation (BDL) induced cholestatic liver damage 
RNA samples from bile-duct-ligated mice over the course of 14 days were kindly provided by K. Abshagen 
(Rostock). The surgical procedure was carried out as previously described by Abshagen et al. [109, 110]. 
Male Balb/c mice (n = 3–5) were anesthetized with isoflurane (1.5 vol%) and midline laparotomy was 
performed. Then the common bile duct was ligated three times using non-resorbable sutures (polyester 
5–0; Catgut, Markneukirchen), and cut between the two gut-near ligatures. The sham-operated mice 
underwent a laparotomy with exposure but no ligation of the bile duct (0h). The animals were allowed to 
recover from anesthesia and surgery under a red warming lamp and received drinking water containing 
Metamizole as an analgesic. The mice were held in single cages and were sacrificed after 0, 6, 12, 18, or 30 
hours, respectively after 2, 5, or 14 days. Blood and liver samples were preserved (n =3–5). Sham-operated 
animals without BDL served as controls (n = 5). RNA samples were used for gene expression analysis 
performed with quantitative real-time PCR (qPCR).  
2.8.8 TGFα/cMyc transgenic mouse model for hepatocarcinogenesis 
Liver tissue of double transgenic TGFα/cMyc mice was kindly provided by A. Piiper (Frankfurt). The mice 
were generated by crossing c-Myc mice with TGF-α mice as described in [111]. Hepatocarcinogenesis in 
male TGFα/cMyc mice was induced by the addition of ZnCl2 to the drinking water. The development of 
liver tumors was monitored by Gd-EOBDTPA-enhanced magnetic resonance imaging [112]. Liver tumors 
and normal liver tissue were then resected and snap-frozen at −80 °C for further analysis. For quantitative 
real-time PCR, RNA was extracted as described in 2.5.1.  
 
 
 
Figure 5 AON application scheme in MDR2-KO mice 
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2.9 Human Patient Collectives 
Publicly available databases such as Oncomine® Research Edition and Arrayexpress, and data from collaborative 
collaborative projects (GSE7980, Mannheim, Frankfurt and Regensburg), were used to analyze TGF-β isofom 
isofom expression in human patient samples. The data was analyzed with the GraphPad Prism 6 tool. The 
expression values were referred to normal liver samples and/or to surrounding non-cancerous tissue of the same 
same patient. In total, seven HCC collectives and seven cirrhosis/precancerous stage collectives were analyzed 
analyzed using Oncomine® Research Edition. Different criteria were applied for the analysis of TGF-β isoform 
isoform expression in HCC vs normal, in cirrhosis/precancerous stages vs normal, and in HCC vs cirrhosis/ 
precancerous stages when the p-value was ≤ 0.05. For the data retrieved from Arrayexpress (GSE7980), the 
the following criteria were used: (1) significance below 0.05 (p-value < 0.05), (2) number of cohorts with significant 
significant differences in TGF-β1 and TGF-β2 expression (≥ 3), and (3) tendency of TGF-β1 and TGF-β2 expression 
expression within different cohorts (up- or down-regulated). In two cohorts (GSE7980 and Regensburg), the 
the clinicopathological parameters were correlated with TGF-β2 expression ( 
Table 7). An overview of all patient cohorts used in this study is listed in Table 5 and Table 6. 
2.10 Statistical Analysis 
Error bars represent standard d to the mean and were used unless described otherwise; two-tailed Student-
t tests or one-way ANOVA were used to calculate the p-values. Additionally, Pearson correlation was 
performed. Differences were considered to be significant if the calculated p-value was *p ≤ 0.05, **p≤ 0.01, 
***p≤ 0.001; the p-values were not significant if not indicated. GraphPad Prism (GraphPad Software, 
Version 6) was used unless described otherwise. 
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3 Results 
3.1 TGF-β2 Incidence in Mice and Men 
3.1.1 TGF-β2 expression in murine primary hepatocytes and hepatic stellate cells 
Hepatocytes represent the major cell type of the liver and account for 80% percent of the liver mass. They 
are involved in metabolic, endocrine, and secretory processes and therefore widely used for hepatic 
toxicology and drug metabolism studies. Isolated hepatocytes are known to lose their specific functions 
and dedifferentiate when cultured on a normal plastic or collagen monolayer [113]. Hepatocytes cultured 
in a collagen sandwich maintain stable differentiated functions and hepatic polarity. As part of this work, 
freshly isolated hepatocytes were cultured either on collagen sandwich (CS) or on collagen monolayer (CM) 
and TgfB1 and TgfB2 mRNA expression was determined (Figure 6A). In both settings, the expression of 
TgfB1 and TgfB2 increased with culture duration after 24 and 48 hours and induction was higher in CS for 
both cytokines. Secretion of TGF-β2 was lower, but induction of TGF-β2 secretion after 48 h on CM was 
stronger compared to TGF-β1 (Figure 6B). Stimulation of CM-cultured hepatocytes with TGF-β1 led to 
increased TGF-β1 secretion up to 4700 pg/ml after 2 h, plateauing at constant levels of approximately 2000 
pg/ml after 10 h. In contrast, TGF-β2 secretion constantly increased over time but to a lesser extent (Figure 
6C). 
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Figure 6 Expression and secretion of TGF-β1 and TGF-β2 by primary mouse hepatocytes after 24 and 48 hours of 
culture on collagen monolayer (CM) or collagen sandwich (CS). (A) Relative expression of TgfB1 (upper panel) and 
TgfB2 (lower panel) was analyzed using Sybrgreen-based qPCR. (B) Secretion of TGF-β1 and -β2 by hepatocytes 
was measured using Quantikine ELISA. (C) Hepatocytes were stimulated with 1 ng/mL TGF-β1 cytokine and 
secretion was measured at the indicated time points using Luminex assay. The data represents the summary of 3-
4 independent experiments and the error bars represent the standard error. Adapted and modified according to 
[114]. 
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Figure 7 TGF-β isoform expression and secretion by quiescent (2 days) and culture-activated (8 days) primary mouse 
hepatic stellate cells (HSCs). After 2 and 8 days, (A) relative TgfB1 and TgfB2 expression was determined by qPCR 
and referred to HSCs cultured for 2 days, and (B) secretion of TGF-β1 and TGF-β2 was measured without stimulation 
using a Luminex ELISA (left panel). The protein content of the HSC lysates was quantified using Quantikine ELISA. 
The data is presented as the mean of 3 independent experiments and the error bars represent the standard 
deviation. Adapted and modified according to [114]. 
 
Hepatic stellate cells are described as the main fibrogenic cell type and as extracelluar matrix producers in 
the liver. HSCs are located in the Space of Disse between sinusoids and hepatocytes. Upon liver damage, 
HSCs express and secrete TGF-β1, which in turn activates paracrine signaling and affects all other cell 
types. In this study, TgfB2 mRNA expression and TGF-β2 secretion were compared in quiescent (2 days) 
and activated (8 days) primary mouse HSCs. Expression of both cytokines increased within 8 days during 
cell culture activation (Figure 7A). Mainly TGF-β1 (~16,000 pg/mL) was secreted after 8 days, while only 
about 850 pg/ml of TGF-β2 were detected at that time point. Furthermore, the secretion of both TGF-β 
isoforms was demonstrated to be increased ~10-fold after 8 days when compared to the 2-day time point 
(Figure 7B) (left panel). The ELISAs of total cell lysates revealed different TGF-β protein amounts in the 
cells than the measured secreted amounts. Intracellular TGF-β2 (day 2: ~200-fold, day 8: ~10-fold) levels 
increased about 10-fold between 2 and 8 days, while TGF-β1 content remained stable but markedly higher 
(Figure 7B (right)). This fact suggests the assumption that there is a cytokine-specific maximum protein 
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level in the cells, which is reached for TGF-β1 already on day 2. All produced cytokines passed the limit and 
were then secreted continuously. Thus, 8- to 10-fold levels of both cytokines were found in the supernatant 
compared to the cell lysates on day 8. 
It is well known that TGF-β1 signaling plays a pivotal role in HSCs and in their transdifferentiation to 
myofibroblasts [47]. TGF-β1 treatment of quiescent HSC leads to Smad phosphorylation. Related to this, 
and to examine whether TGF- β2 has the same effect, freshly isolated primary HSCs were treated 
separately with both cytokines over the course of 24 h. TGF-β2 could induce Smad phosphorylation (up to 
6 h), although it was not persistent up to 24 h (Figure 8).  
 
Figure 8 Immunoblot of murine primary HSCs for phospho-Smad 1/3. Immunoblot analysis of Smad1, 2, and 3 
phosphorylation upon stimulation with 10 ng/ml TGF-β1 or TGF-β2 recombinant protein. Stimulation time and 
cytokines were used as indicated in the figure.  
3.1.2 TGF-β2 in human liver cell lines 
3.1.2.1 Human LX-2 
To translate our findings to the human system, we examined the human HSC cell line LX-2, which retains 
key features of human primary HSCs. First, the expression of TGF-β1 and -β2 was examined, revealing no 
change from day 2 to day 4 (Figure 9A). Secretion of TGF-β1 was found to be about 1.5 times higher than 
that of TGF-β2 after 4 days (Figure 9B). Next, the impact of secreted TGF-β isoforms on TGF-β receptor 
expression in HSC was investigated by stimulating HSCs with either 10 ng/ml TGF-β1 or TGF-β2 
recombinant protein. Since it is known that TGF-β1 can influence the expression of its signaling receptors, 
the TGF-β receptor expression in LX-2 cells was then analyzed [115]. Stimulation with 10 ng/ml TGF-β1 for 
1 and 24 hours either decreased or did not alter TGF-β receptor expression, while stimulation with TGF-β2 
decreased receptor expression after 1 h, but notably induced TGF-β receptor expression after 24 h 
(pendoglin ≤ 0.027) (Figure 9C). These mRNA results suggested a different impact of TGF-β2 on HSC 
signaling and thus Smad phosphorylation was investigated. After 1 or 24 hours of TGF-β1 and -β2 
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treatment, phosphorylation of Smad1, 2, and 3 was found to be similar, whereas 24h TGF-β2 pretreatment 
of LX-2 cells led to sensitization of the cells towards subsequent cytokine stimulation. Here, 
phosphorylation of Smad1 was seen to be induced, which could be in line with the receptor upregulation 
seen on the mRNA level (Figure 10). 
 
Figure 9 mRNA expression and secretion of TGF-β1, TGF-β2, and TGF-β-receptors in LX-2 cells. (A) Gene expression 
of TGF-β1 and -β2 after 2 and 4 days and (B) secretion after 4 days of cell culture. (C) Stimulation of TGF-β1 or TGF-
β2 with 10 ng/ml recombinant protein and subsequent qPCR analysis of TGF-β receptor expression. The levels of 
TGF-β receptors in unstimulated cells at the time points indicated served as references. Adapted and modified 
according to [114]. 
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Figure 10 Immunoblot analysis of Smad1, 2, and 3 expression and phosphorylation upon stimulation with either 10 
ng/ml TGF-β1 or TGF-β2 cytokine. (A) Stimulation time and cytokines were used as indicated in the figure. (B) LX-
2 cells pretreated for 24 h with TGF-β2 are sensitized towards subsequent cytokine-induced Smad1 signaling. The 
first treatment lasted for 24 hours as indicated and was followed by a 1-h treatment. Adapted and modified 
according to [114]. 
3.1.2.2 Human HCC cell lines  
TgfB2 and TgfB1 mRNA expression levels in seven different hepatocellular carcinoma cell lines and one 
hepatoblastoma cell line (HuH6) were investigated to get an insight into TGF-β2 involvement in late-stage 
CLD. While very low amounts of TgfB2 were expressed in HuH6, PLC, and HepG2 cells, TgfB2 expression 
was higher in FLC-4, Hep3B, HLF, HLE, and HuH7 cells with decreasing extent in the respective order 
(Figure 11A). After 4 days of culture, secretion of TGF-β2 was low in PLC, HLE, HepG2, and HuH6 cells, but 
high and in a similar range as TGF-β1 in Hep3B, HuH7, HLF, and FLC-4 cells (Figure 11B). Interestingly, in 
Hep3B and HuH7 cells, TGF-β2 secretion even exceeded TGF-β1 secretion significantly (pHep3B ≤ 6E–05; 
pHuH7 ≤ 0.0024). TgfB1 and TgfB2 expression correlated well in HCC cell lines (RTGF-β1-/TGF-β2 =0,811, p = 0,015) 
(Figure 11C), and mRNA expression of TgfB1 and TgfB2 correlated with secretion of the respective TGF-β 
isoform. Interestingly, TGF-β1 and TGF-β2 secretion did not coincide (Figure 11D). 
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Figure 11 Different appearance of TGF-β1 and TGF-β2 expression in human HCC cell lines and one hepatoblastoma 
cell line. (A) TGFB1 and TGFB2 expression analysis by qPCR in 7 HCC cell lines and one hepatoblastoma cell line. (B) 
After 4 days in culture, TGF-β isoform secretion was determined by performing ELISA. (C) Pearson correlation of 
TGF-B1 versus TGFB2 expression and (D) TGFB isoform expression versus TGFB secretion in all HCC cell lines. *p ≤ 
0.05, **p ≤ 0.01, ***p ≤ 0.001. Adapted and modified according to [114]. 
3.1.2.3 TGF-β2 knockdown in human HuH7 and LX-2 cells using a TGF-β2-specific anti-
sense oligonucleotide (AON) 
 
A TGF-β2 knockdown experiment using an isoform-specific antisense oligonucleotide (AON) was performed 
in one HCC cell line (HuH7) and one human hepatic cell line (LX2) presenting high TGF-β2 expression. 
Successful downregulation of TGF-β2 in both cell lines (Figure 12 (A) revealed the suitability of TGF-β2 
AON as a functional tool for studying the role of TGF-β2 in vitro. 
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Figure 12 AON-mediated TGF-β2 knockdown in HuH7 and LX-2 cells. (A) Validation of knockdown efficiency in HuH7 
(left panel) and LX-2 cells (right panel) analyzed by qPCR after 48 h and referred to non-treated cells. For both cell 
lines, an AON concentration of 20 nmol was used. Adapted and modified according to [114]. 
3.1.3 TGF-β2 expression in animal models of chronic liver disease 
To confirm our findings, TGF-β1 and -β2 expression was analyzed in different animal models of chronic liver 
disease, each presenting distinct attributes of the disease process. 
3.1.3.1 Expression of TgfB1 and TgfB2 in chemically induced fibrosis of CCl4-challenged 
mice 
A widely used model for studying liver regeneration and fibrosis is hepatic intoxication with carbon 
tetrachloride (CCl4). A single CCl4 dose leads to acute, but reversible liver damage followed by 
regeneration. Within 6 days, similar dynamics of TgfB2 and TgfB1 expression were shown by quantitative 
real-time qPCR (Figure 13). Two days after CCl4 administration, the expression of both isoforms was at 
maximum (Figure 13A). Interestingly, collagen 1A expression consistently peaked on day 2. The study was 
then extended to chronic CCl4 treatment. The mice received either one CCl4 injection or three CCl4 
injections within one week, or, for chronic treatment, twice per week for six weeks. In all setups, CCl4 
treatment significantly enhanced the expression of TgfB1 and TgfB2, but the highest expression of both 
isoforms was observed after six weeks of chronic treatment (Figure 13B). Performing Pearson correlation 
analysis in individual mice that had been treated for six weeks with CCl4, positive correlation of collagen 
1A1 expression with both TGFB isoforms was visible (Figure 13C). 
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Figure 13 Expression of TgfB1, TgfB2, and Collagen 1a1 upon acute and chronic CCl4-induced liver damage. (A) The 
dynamics of TgfB1, TgfB2, and Collagen 1a1 expression over the course of six days were determined by qPCR in 
comparison to untreated animals. (B) Examination of TgfB1 and TgfB2 mRNA expression 24 h after 1 CCl4 injection, 
3 injections within one week, or two injections per week for six weeks as indicated. (C) In 7 individual mice harboring 
chronic liver damage, TgfB1 and TgfB2 expression correlated with Collagen 1a1 expression (6 weeks of treatment). 
The Pearson coefficients were rTGF-β1/TGF-β2 = 0.891, rTGF-β1/Col1A = 0.723, and r = 0.701, respectively. Adapted and 
modified according to [114]. 
3.1.3.2 TGF-β isoform expression in models of biliary-derived liver disease 
Liver fibrosis comprises different etiologies; among these, cholestatic liver disease and biliary fibrosis 
account for a considerable part. An established animal model for studying cholestasis is ligation of the 
common bile duct (BDL). The expression patterns of TgfB1 and TgfB2 were analyzed over the course of up 
to 14 days after BDL and revealed an elevation of TgfB1 and TgfB2 expression. Only a slight induction of 
TgfB1 expression (~4-fold as compared to 0 h) was found in this time period, while TgfB2 was strongly 
induced after 14 days (~155-fold as compared to 0 h) (Figure 14A). Time-resolved high-throughput 
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quantitative Taqman qRT-PCR (Fluidigm) [114] analysis revealed parallel induction of TgfB2 and different 
fibrosis markers such as TgfB1, Acta2, Col1a1, Col4a3, Col8a1, and Timp1 (Figure 14B).  
 
Figure 14 Expression patterns of TgfB1, TgfB2, and fibrotic markers in bile-duct-ligated mice (BDL). (A) TgfB1 and 
TgfB2 expression were determined over the course of 14 days after bile duct ligation (BDL). Relative expression 
was normalized to expression of GAPDH and referred to the mean ΔCt of all samples. (B) Fluidigm-based gene 
expression analysis of typical fibrosis markers displayed in a heat map. The color represents the expression level of 
the gene. Red represents high expression, while blue represents low expression. *p < 0.01; **p < 0.005; ***p < 
0.001. Adapted and modified according to [114]. 
To confirm a potential involvement of TGF-β2 in the cholestasis process, TgfB1 and TgfB2 expression was 
additionally determined in MDR2-KO (Abcb4-/-) animals, a reproducible mouse model of chronic biliary 
liver disease. MDR2-deficient mice spontaneously develop progressive biliary damage resembling human 
primary sclerosing cholangitis (PSC). MDR2-KO animals showed significant TgfB2 upregulation in early 
stages (3 months) and at late time points (15 months) over the course of 3 to 15 months compared to the 
correspondingly aged wild-type mice, while TgfB2 was significantly increased at 3 months and 9 months 
(up to 10-fold). TgfB1 expression was notably weaker than TgfB2 expression (up to 2.5 times) (Figure 15A). 
To visualize the change of TGF-β isoform expression over time, line graphs of fold change expression were 
generated using 3-month old wild-type animals as a reference for all time points (Figure 15B). Interestingly, 
TgfB2 expression in wild-type and MDR2-KO animals seemed to increase over time, while expression of 
TgfB1 was consistent and lower than TgfB2 in both mice groups at all time points. As the MDR2-KO model 
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covers a progression of biliary disease from early precancerous stages to cancerous stages, such as HCC, 
tumors derived from MDR2-KO animals and their corresponding surrounding tissue were analyzed for 
TgfB1 and TgfB2 expression. No further increase in the expression of both TgfB isoforms could be shown 
in tumors when compared to the corresponding surrounding tissue (Figure 15C). The highest TgfB 
expression for both cytokines had already taken place in the surrounding tissue.  
 
Figure 15 Expression levels of TgfB1 and TgfB2 in MDR2-KO mice. (A) TgfB1 and TgfB2 mRNA expression in MDR2-
KO mouse livers after 3, 6, 9, and 15 months was referred to the liver tissue of wild-type animals of the same age. 
(B) TgfB isoform expression over time. (C) Comparison of TgfB1 and TgfB2 expression in the surrounding tissue and 
the respective tumor tissue of MDR2-KO mice aged 80-86 weeks. Adapted and modified according to [114]. 
3.1.3.3 Characterization of TgfB1 und TgfB2 expression in murine HCC models 
As expression of TgfB2 was upregulated in aged MDR2-KO mice, another experimental liver carcinogenesis 
model was investigated. Overexpression of c-myc in the liver leads to constant hepatocyte proliferation 
and eventual HCC. Epithelial hyperplasia in the liver and even neoplastic transformation is reached when 
TGF-α is overexpressed, which leads to a high incidence of tumor development over time. In the TGF-α 
and c-myc animal model applied here, c-myc and TGF-α are co-expressed and therefore the development 
of liver tumors is very likely. The expression of TgfB2 and TgfB1 in tumors of TGF-α/c-Myc mice was higher 
than in normal tissue of the same animals, but overall TgfB2 mRNA expression was significantly elevated 
in tumors of TGF-α/c-Myc animals (Figure 16A). 
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Figure 16 TGF-β isoform expression in TGFα/cMyc, a murine HCC model. (A) qPCR for TgfB1 and TgfB2 expression in 
paired samples of TGFα/cMyc mice. Adapted and modified according to [114]. 
3.1.4 Expression data and correlations of human specimens from microrarray data anal-
ysis 
Animal models provide several advantages when it comes to studying target expression and function, 
including the study of the liver as a whole organ and the ability to study the mechanistic background of 
disease development. Nevertheless, no mouse model exactly reflects the complex human liver and human 
liver diseases with all variables and features. Hence, we aimed to translate our findings to the patient’s 
situation. 
3.1.4.1 TGFB1 and TGFB2 expression in human HCC and cirrhosis patients based on On-
comine® Research Edition analysis 
Publicly accessible microarray repositories were searched for human HCC and cirrhotic patients( 
Table 6). The expression data of the TGF-β isoforms was then analyzed. In four out of seven studies, TGFB2 
upregulation was reported, independent of etiology, whereas only one dataset described TGFB2 
downregulation (Figure 17). In the former collectives, TGFB2 was one of the top 5–10% of upregulated 
genes, while downregulation was less remarkable (in 25% of downregulated genes). Investigating TGFB1 
expression in the same cohorts, two studies reported upregulation (in 25% of the most upregulated genes) 
and another two reported downregulation (in 25% of the top downregulated genes) (Table 6). To underline 
a potential role of TGFB2 in human hepatocarcinogenesis, the survival analysis and the clinicopathological 
parameter of the GSE1898/4024 collectives were correlated with TGFB2 regulation. Groups with high and 
low TGFB2 expression were defined. Notably, high TGF-β2 expression correlated with a poorer survival 
rate (p < 0.01) (Kaplan-Meier-plot), but not with other clinical features like AFP levels, tumor size, 
differentiation grade, cirrhosis, and hepatoblast vs. hepatocyte subtype (data not shown; published in 
[114]).  
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No. of Cohort in 
Figure 17 
Publication Reference Tissue 
8 Mas Liver, Mol Med. 2008 [116] Cirrhosis vs. normal 
9 Wurmbach Liver, Hepatology 2007 [117] Cirrhosis vs. normal 
10 Wurmbach Liver, Hepatology 2007 [117] Dysplasia vs. normal 
11 Chiang Liver 2, Cancer Res.2008 [118] 
HCC vs. Liver Cancer Type: Liver Cancer Pre-
cursor 
12 Mas Liver, Mol Med. 2008 [116] 
HCC vs. Liver Cancer Type: Liver Cancer Pre-
cursor 
13 
Archer Liver, Cancer Epidemiol Biomarkers 
Prev .2009 [119] 
HCC vs. Liver Cancer Type: Liver Cancer Pre-
cursor 
14 Chen Liver. Mol Biol Cell. 2002 [120] 
HCC vs. Liver Cancer Type: Liver Cancer Pre-
cursor 
Table 5 Liver cancer precursor and cirrhosis cohorts used for the analysis of TGFB1 and TGFB2 expression based on 
Oncomine® Research Edition. Adapted and modified according to [114]. 
    Overexpression Underexpression 
TGFB2 Publication Samples 
Total no. 
of meas-
ured genes 
TGFB2 
gene 
rank 
Fold 
change 
(median 
centered 
ratio) 
p-
valu
e 
TGFB2 
gene 
rank 
Fold-
change 
(median 
centered 
ratio) 
p-value 
1 
Chen Liver. 
Mol Biol 
Cell. 2002 
[120] 
197 10.802 
5239 (in 
top 
49%) 
1.107 
0.2
21 
2569 
(in top 
24%) 
-1.258 0.006 
2 
Guichard 
Liver. Nat 
Genet. 2012 
[121] 
185 18.823 
838 (in 
top 5%) 
1.114 
1.0
8E-
14 
17148 
(in top 
92%) 
1.114 1.000 
3 
Guichard 
Liver 2. Nat 
Genet. 2012 
[121] 
52 18.823 
787 (in 
top 5%) 
1.103 
4.3
2E-
6 
17195 
(in top 
92%) 
1.103 1.000 
4 
Mas Liver. 
Mol Med. 
2008 [116] 
115 12.603 
890 (in 
top 8%) 
1.191 
1.5
6E-
6 
3547 
(in top 
29%) 
-1.076 0.003 
5 
Roessler 
Liver. Can-
cer Res. 
2010 [122] 
43 12.603 
4250 (in 
top 
34%) 
1.194 
0.0
46 
5540 
(in top 
44%) 
-1.029 0.118 
6 
Roessler 
Liver 2. 
Cancer Res. 
2010 [122] 
445 12.624 
5015 (in 
top 
40%) 
1.053 
0.0
01 
5115 
(in top 
41%) 
-1.034 0.004 
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Table 6 HCC sample cohorts used for the analysis of TGFB1 and TGFB2 expression based on Oncomine® Research 
Edition. Total number of samples, total number of genes measured, p-values, gene ranks, and fold change are given 
for TGFB1 and TGFB2 as indicated. Additionally, the table summarizes in which range of differentially expressed 
genes the respective gene was found in the study (top %). ND = not detected in the study. Adapted and modified 
according to [114]. 
 
Given the downregulation of TGFB2 in HCC compared to surrounding liver tissue (Figure 17C), which is 
usually cirrhotically dearranged, TGFB1 and TGFB2 expression was also evaluated in pre-neoplastic stages, 
such as cirrhosis, using the Oncomine® database. In precancerous and cirrhotic stages in human patients, 
both isoforms were found to be upregulated compared to normal liver tissue (Figure 17B). A continuous 
increase of TGFB1 expression from healthy tissue via cirrhosis and further to HCC was noticed (Figure 17 
7 
TCGA Liver. 
No Associ-
ated Paper. 
2012 
212 18.823 
792 (in 
top 5%) 
1.233 
3.4
0E-
15 
ND ND ND 
TGFB1 Publication Samples 
Total no. 
of meas-
ured genes 
TGFB1 
gene 
rank 
Fold 
change 
(median 
centered 
ratio) 
p-
valu
e 
TGFB1 
gene 
rank 
Fold 
change 
(median 
centered 
ratio) 
p-value 
1 
Chen Liver. 
Mol Biol 
Cell. 2002 
[120] 
197 10.802 
10452 
(in top 
97%) 
-1.557 
1.0
00 
512 (in 
top 
5%) 
-1.557 
1.56E-
12 
2 
Guichard 
Liver. Nat 
Genet. 2012 
[121] 
185 18.823 
5712 (in 
top 
31%) 
1.013 
0.0
60 
12282 
(in top 
66%) 
1.013 0.940 
3 
Guichard 
Liver 2. Nat 
Genet. 2012 
[121] 
52 18.823 ND ND ND 
11608 
(in top 
62%) 
1.007 0.820 
4 
Mas Liver. 
Mol Med. 
2008 [116] 
115 12.603 
1784 (in 
top 
15%) 
1.513 
1.4
0E-
4 
X X X 
5 
Roessler 
Liver. Can-
cer Res. 
2010 [122] 
43 12.603 
1836 (in 
top 
15%) 
2.225 
3.0
9E-
4 
5267 
(in top 
42%) 
-1.071 0.093 
6 
Roessler 
Liver 2. 
Cancer Res. 
2010 [122] 
445 12.624 
5677 (in 
top 
45%) 
1.098 
0.0
43 
3088 
(in top 
25%) 
-1.111 3.69E-7 
7 
TCGA Liver. 
No Associ-
ated Paper. 
2012 
212 18.823 
5854 (in 
top 
32%) 
1.027 
0.0
21 
12130 
(in top 
65%) 
1.027 0.979 
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A-C, right panel). In contrast, in cirrhotic tissue, TGFB2 expression was higher than in the normal liver and 
even stronger than in HCC. This dissimilar expression of the two isoforms in precancerous and cirrhosis 
stages compared to HCC hints at contradirectional regulation of TGFB1 and TGFB2 in the progression from 
cirrhosis to HCC (Figure 17D). 
Similar to our results in liver tissue, serum analysis of human cirrhosis and hepatocellular carcinoma patients 
in comparison to healthy donors revealed a tendency towards higher TGFB2 levels in cirrhotic sera. 
Intriguingly, the TGFB2 amounts were found to be the lowest in sera of HCC patients compared to patients 
with cirrhosis and even compared to healthy patients. This data is consistent with the Oncomine® gene 
expression data showing higher TGFB2 expression in precancerous and cirrhotic stages and lower 
expression in HCC (Figure 18).  
 
Figure 17 TGFB1 and TGFB2 expression in human HCC, cirrhosis, and precancerous stages using the Oncomine® 
Research Edition database. (A) TGFB1 (right panels) and TGFB2 (left panels) expression in human HCC versus 
normal stages were examined using in silico analysis on the Oncomine® database platform. (A) Gene expression in 
HCC vs. normal liver was analyzed. The numbers correspond to the list of references in Table 6. (B-C) Gene 
expression in precancerous stages/cirrhosis vs, normal or cancer vs. precancerous stages/cirrhosis was analyzed. 
The numbers correspond to the list of references in Table 5. (D) Scheme for potential TGFB1 and TGFB2 regulation 
during disease progression. p-values of < 0.05 were set and the p-value for a given gene is its p-value for the median-
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ranked analysis. Note: In the Mas Liver data (collective numbered with 8), TGF-β2 was also downregulated 
significantly (p = 2.54E-5, top 23%, median rank 2790) in cirrhosis vs. normal tissue. Adapted and modified 
according to [114]. 
 
Figure 18 TGFB2 levels in human sera of different entities: Systemic TGFB2 levels in sera of healthy, cirrothic, and 
HCC patients using a specific TGFB2 enzyme-linked immunosorbent assay. Each single dot represents an individual 
patient.  
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3.1.5 In vivo targeting of TgfB2 using antisense oligonucleotides (AONs) 
Our findings regarding TgfB2 expression in mice and human so far indicate that TgfB2 might represent a 
potentially relevant target in CLD. To test this hypothesis, TGFB2 was specifically silenced in vivo in the 
MDR2-KO mouse model, which represents biliary and other inflammation-associated liver damage. 
TGFB2 mRNA was specifically targeted using antisense oligonucleotides (AONs). Their simple generation 
and design as well as their various application opportunities make them an attractive tool for gene function 
investigations and a therapeutic agent. Antisense-based therapies are actually in use in many preclinical 
and clinical trials for various types of disease and have been shown to be well-tolerated by patients. 
3.1.5.1 Antisense oligonucleotides (AONs) as a tool in vivo  
To analyze the effect of TGFB2 silencing on liver fibrosis and inflammation, the TGFB2-specific antisense 
oligonucleotide (ASP0047) was used. ASP0047 represents a 17-mer full phosphorothioate Locked Nucleic 
Acid (LNA)-modified antisense oligodeoxynucleotide ‘4+4’ gapmer that selectively targets TGFB2.  
 
Figure 19 Sequence of the TGFB2-directed AON ASPH0047. The TGF-β2-directed AON ASPH0047 was engineered as 
a 17-mer full phosphorothioate LNA-modified antisense oligodeoxynucleotide ‘4+4’ gapmer. A scramble control 
oligo C30047 (Co) was used to control for non-sequence-specific biological effects of oligonucleotides.[123] 
3.1.5.2 Biodistribution and physiological compatibility of AONs 
The hepatotropic efficiency of the TGFB2-targeting AON for the liver was determined after subcutaneous 
(s.c) or intraperitoneal (i.p.) injection into Balb/c wild-type mice (Figure 20A). The liver toxicity of ip and sc 
AON application in wild-type Balb/c mice was analyzed using a standard liver plasma parameter. No 
negative effects of the AON at a concentration of 10 mg/kg of body weight was recorded after 24 h or 5 
days following application (Figure 20B). The body weight as well as the liver/body weight ratio were not 
affected by the AON treatment (Figure 20C). In the liver tissue of Balb/c mice, an AON labeled Digoxigenin 
was visualized by performing immunohistochemistry. The AON accumulated in the Space of Disse, but 
was not detectable in hepatocytes (Figure 21A). Similar observations were made in MDR2-KO mice. In 
cholestatic mice, the AON accumulated along the bile ducts and portal areas. Livers of Balb/c wild-type 
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and MDR2-KO animals were then co-stained for specific liver cell type markers such as CD31 (LSEC), 
Desmin (HSC), αSMA (aHSC),S100A4 (FSP1) (KC) Elastin (PF), and the AON (Digoxigenin) by means of 
immunofluorescence. Interestingly, in MDR2-KO animals the AON accumulated in LSECs, hepatic stellate 
cells (HSC), and Kupffer cells (Figure 21B), whereas in Balb/c mice, it was solely found in CD31-positive cells, 
a marker for liver sinusoidal endothelial cells (LSEC).  
To investigate whether TgfB2 expression and TgfB2-silencing AON accumulation are localized in same cell 
types, a magnetic-bead-based simultaneous four liver cell type isolation for hepatocytes (HC), liver 
sinusoidal endothelial cells (LSEC), Kupffer cells (KC), and hepatic stellate cells (HSC) was performed in 6 
Balb/c mice following qPCR for TgfB2 mRNA expression. Noticeably, TGF-β2 mRNA expression was found 
to be the highest in non-parenchymal cells by qPCR, e.g., in KCs, LSEC, and HSCs (Figure 21c), thus 
showing a similar distribution as the AON in MDR2-KO mice.  
 
Figure 20 AON biodistribution and safety tolerability. (A) Subcutaneous (s.c.) and intraperitoneal (i.p.) TgfB2-
directed AON application in Balb/c mice did not alter (B) liver parameters such as AST and ALT nor (C) the body 
weight or liver/body weight ratio of the respective animals. Each dot represents one animal.  
 54 
 
Figure 21 Cell-type-specific localization of  TGF-β2-directed AONs by means of immunohistochemistry.TgfB2 
expression after 4 liver cell type isolation and AON co-immunofluorescence with cell type markers. (A) In wild-type 
Balb/c and MDR2-KO mice, the TGF-β2-specific AONs were enriched in sinusoidal areas of the liver tissue as 
confirmed by immunohistochemical staining of labeled AONs. (C) Magnetic-bead-based 4 liver cell type isolation 
following qPCR for TGFB2 expression displayed TGF-β2 abundance in the non-parenchymal compartment, in 
particular in Kupffer cells (n=6). (B) Immunofluorescence revealed co-localization of the AONs (red) with non-
parenchymal cell markers, i.e., αSMA, desmin, elastin, S100A4, and CD31 (each green). Hepatocyte nuclei are 
stained in blue by TO-PRO®-3. 
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3.1.6 Efficient TgfB2 downregulation in cholestatic MDR2-KO mice and its impact on fi-
brosis and inflammation  
3.1.6.1 Fibrosis 
With the intention of ameliorating or even blocking fibrogenesis and inflammation in cholestatic liver 
disease through downregulation of TGFB2, MDR2-KO mice were treated for four weeks with the AON, 
starting with an oligo push in the first week. No impact was detected on body weight and liver/body weight 
ratio nor on liver function parameters; thus no toxicity for the liver was ensured (Figure 22A-B). 
Remarkably, TgfB2 mRNA levels were efficiently decreased in MDR2-KO mice after AON application 
(~12.7-fold), characterizing the AON as an effective tool for silencing TGFB2 expression. In addition, 
systemic TGFB2 plasma levels were also found to be reduced in MDR2-KO mice treated with the AON 
compared to untreated and control oligo-treated animals (Figure 22C-D).  
 
Figure 22 TgfB2-specific AON treatment of cholestatic MDR2-KO mice. (A) Treatment with control or TgfB2-specific 
AONs did not alter the body weight of any of the animals. (B) Liver parameters of Balb/c and MDR2-KO mice after 
administration of control oligos (Co) and TGF-β2-specific AONs. ALT, AST, and Alkaline phosphatase plasma levels 
 56 
were higher in MDR2-KO mice than in Balb/c wild-type animals. Treatment with specific or control AON did not 
alter the liver parameters. (C) TgfB2 was significantly downregulated in Balb/c and MDR2-KO animals treated with 
AON. * p ≤ 0.05, ***p ≤ 0.001. (D) After AON application, the TgfB2 level in plasma was reduced compared to 
control oligo-treated and untreated MDR2-KO mice.  
In order to detect the impact of the TgfB2-targeting AON on fibrogenesis, multiple common fibrosis markers 
were examined. Since excessive accumulation of extracellular matrix, in particular collagen, is a hallmark 
of fibrosis, the hydroxyproline content in the livers of MDR2-KO mice was determined quantitatively. No 
difference was observed in AON or control oligo-treated wild-type animals compared to untreated Balb/c 
mice. Significant hydroxyproline reduction was achieved in MDR2-KO mice upon AON application in 
comparison to non-treated and control oligo-treated MDR2-KO mice. The hydroxyproline content and the 
Col1a1/Col3a1 mRNA level of MDR2-KO mice were generally higher than those of Balb/c wild-type animals, 
while no difference was detected between the treated and non-treated groups (Figure 23A-B). Collagen 
deposition was then analyzed by performing Sirius Red staining. Compared to untreated MDR2-KO mice, 
AON-treated mouse livers showed significant downregulation (~56%) of collagen accumulation while wild-
type animals showed no differences in collagen deposition between the untreated and treated groups 
(Figure 23C). To further examine the anti-fibrotic potential of TgfB2, some typical fibrosis markers were 
investigated on the mRNA expression level. Unlike TgfB2, TgfB1 expression was not elevated in MDR2-KO 
animals. When comparing MDR2-KO mice with wild-type animals, TgfB1 and Ctgf expression was similar 
in all tested livers. Timp1 and α-SMA expression were slightly increased in MDR2-KO mice, but AON 
treatment showed no significant impact on their expression (Figure 24A). Since α-SMA mRNA expression 
appeared very divergent, α-SMA protein expression was further analyzed by means of 
immunohistochemistry and immunoblot. Positive α-SMA staining was significantly reduced (~35%) upon 
AON treatment of MDR2-KO mice. This effect was confirmed by immunoblot of MDR2-KO total liver 
lysates (Figure 24 B-D). 
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Figure 23 Collagen expression and deposition after AON-mediated TgfB2 silencing in MDR2-KO mice. (A) AON-
treated MDR2-KO mice showed significantly downregulated hydroxyproline content in the liver compared to 
untreated and control oligo-treated animals. (B) mRNA expression of two collagen types showed no regulation 
after AON or control oligo treatment. (C) Sirius Red staining revealed significant downregulation (~56%) of collagen 
deposition in the tissue of AON-treated MDR2-KO mice compared to untreated MDR-KO mice. * p ≤ 0.05, **p ≤ 
0.01, ***p ≤ 0.001 
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Figure 24 Impact on fibrotic marker expression after AON administration in MDR2-KO mice. (A) TgfB1, Timp1, and 
Ctgf mRNA expression was not changed considerably by TgfB2-directed AON treatment verified by qPCR. (B-C) 
Immunohistochemical staining and quantification demonstrated a decrease of αSMA expression of 35% in AON-
treated animals compared to untreated animals and of 43% compared to animals treated with control oligos. (D) 
Reduction of the αSMA protein level was verified by immunoblot analysis. * p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
3.1.6.2 Biliary damage: MDR2-KO mouse model of sclerosing cholangitis and biliary fi-
brosis  
MDR2-KO mice lack the Mdr2 gene, which encodes for a phospho flipase. Therefore, they must sufficient 
excretion of phospholipids into the bile canaliculus. The external appearance of MDR2-KO mice shows no 
difference compared to age-matched wild types in the course of the first year. Already a few weeks after 
birth, an irregular canaliculi phenotype is visible and the livers of MDR2-KO mice have altered immune 
responses, such as neutrophil-granulocytic infiltrates, proliferating fibroblasts, and ductular reaction (DR) 
in larger portal tracts, in comparison with age-matched control animals. Likewise, these mice develop 
periductal onion-skin fibrosis between bile ducts at an early age [124]. Since histological and macroscopic 
features found in MDR2-KO are similar to human PSC, these mice represent a suitable model for 
mimicking PSC in mice and make it possible to study inflammation-driven fibrosis. 
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Figure 25 Impact of AON treatment on biliary damage and ductular reactions (DR). TgfB2 silencing by AON reduced 
biliary damage and ductular reactions (DR). Using qPCR and immunohistochemical staining, significant 
downregulation of Muc1 as a marker of biliary damage and CK19 as a marker of DR, respectively, was detected in 
AON-treated MDR2-KO mice. * p ≤ 0.05, ***p ≤ 0.001. 
As shown in Figure 24 and Figure 25, MDR2-KO mice exhibit fibrogenic liver rearrangements, periductular 
onion-skin fibrosis, and pronounced ductular reaction (DR) at the age of 18 weeks. AON treatment of 
MDR2-KO mice improved biliary damage and reduced DRs, as demonstrated by CK19 staining of the liver 
tissue (Figure 25A). Analyzing the effect of AON application with respect to biliary damage, Muc1 and Tff2 
expression was investigated in all groups of MDR2-KO animals and the corresponding wild-type animals. 
Muc1, which has been reported to be a marker for biliary disease stages, was downregulated by AON 
treatment. Another marker, Tff2, showed a similar trend, but only in treated mice (Figure 25B).  
3.1.6.3 Inflammation 
Cholestatic liver disease of MDR2-Ko mice is known to be associated with increased bile duct proliferation, 
biliary fibrosis, and pronounced inflammation. Interestingly, staining of the panleukocyte marker CD45 
(Figure 27) and portal area assessment of H&E stained tissue sections (Figure 26) verified a significant 
decrease in the number of infiltrating inflammatory cells in AON-treated MDR2-KO mice. To assess the 
inflammatory status of the mice in more detail, prominent targets such as TnfA, Il6, and Il1B were 
investigated in AON-treated and untreated mice. These targets are known to be induced by M1-type 
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macrophages, which exhibit an inflammatory phenotype. The expression of TnfA, Il6, and Il1B did not 
significantly change between the treated and untreated groups (Figure 27). Remarkably, significantly 
increased expression of PparG, an indicator for reduced liver fibrosis and an affector for macrophages [125, 
126] ,was found in AON-treated MDR2-KO mice. Taken together, these findings point towards 
ameliorated inflammation in the livers of these animals. 
 
Figure 26 Representative H&E images of all mouse groups. H&E staining confirmed inflammation reduction through 
TgfB2-silencing AON treatment in MDR2-KO mice compared to untreated or control oligo-treated MDR2-KO mice. 
All Balb/c mice groups did not show any significant inflammatory infiltration before or after any of the treatments. 
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Figure 27 Immune cell detection in the liver tissue of AON-treated MDR2-KO mice compared to controls. (A) The 
expression levels of TnfA, Il6, and Il1B as typical M1 markers were not elevated in AON-treated groups compared 
to Balb/c mice. The expression of PparG showed significant upregulation in AON-treated mice (right plot). (B) 
Immunohistochemical staining and quantification of CD45 revealed significant downregulation in AON-treated 
MDR2-KO mice. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
The inflammatory niche of the mouse model was further characterized by staining the monocyte 
macrophage marker F4/80 and the neutrophil marker myeloperoxidase (MPO). Untreated Balb/c and 
MDR2-KO mice as well as control oligo-treated groups showed no remarkable F4/80+cell infiltration. 
MDR2-KO animals treated with TGF-β2-silencing AON instead showed significant attraction of F4/80-
positive macrophages, predominantly around portal tracts (Figure 28 A). Similar levels of MPO-positive 
cells were observed in all control groups of Balb/c and MDR2-KO mice. In AON-treated animals, a 
significant increase of MPO-positive cells was visible compared to untreated or control oligo-treated 
animals, suggesting enhanced infiltration of macrophages and neutrophils, although typical inflammation 
parameters were found to be reduced (Figure 28B). 
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Figure 28 Immune cell infiltration into the liver tissue of AON-treated MDR2-KO mice and corresponding controls. 
(A) In AON-treated MDR2-KO mice, liver-resident F4/80-positive macrophages were detected. 
Immunohistochemical staining and quantification of F4/80-positive cells revealed significant upregulation in AON-
treated MDR2-KO mice. (B) In AON-treated Balb/c and MDR2-KO mice, significant MPO upregulation was 
observed, as shown by immunohistochemical staining and quantification. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001  
3.1.7 From mice to men: TGFB2 in human primary sclerosing cholangitis (PSC) and pri-
mary biliary cholangiopathy (PBC) patients  
Cholestatic liver diseases, including primary biliary cholangiopathy (PBC) and primary sclerosing cholangitis 
(PSC), belong to the category of rare diseases. While PBC occurs more often in intrahepatic bile ducts and 
primarily affects women, PSC is more prevalent in men and appears in the intra- and extrahepatic bile 
ducts. Both diseases are characterized by inflammation, portal fibrosis, and strictures of the above-
mentioned bile ducts, which leads to a chronically progressing disease and further to biliary cirrhosis and 
end-stage liver disease [127, 128]. Since biopsies and human material are not taken routinely from these 
patients, they are not commonly available and hence poorly studied.  
In terms of the results found in animal models of biliary-derived liver disease such as BDL and MDR2-KO mice 
mice described in 3.1.3.2, liver tissue samples of PSC and PBC patients (collectives from Regensburg, Mannheim, 
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Mannheim, and Frankfurt) were investigated for their TGFB2 mRNA expression and two cohorts (GSE7980 and 
and Regensburg) were correlated with clinicopathological data. Comparing the expression data of these patients 
patients to normal liver tissue, TGFB2 showed significant upregulation in PSC and PBC patients and significant 
significant correlation with the inflammation grade of both collectives ( 
Table 7). Consistently, in another cohort (GSE79850) comprising nine high-risk patients who ultimately 
needed liver transplantation and seven low-risk patients who responded to UDCA treatment, upregulated 
TGFB2 expression was found in the high-risk patient group. High TGFB2 expression was significantly 
associated with a high Scheuer grade (III and IV). Additionally, high TGFB2 expression correlated well with 
the diagnosis of ductopenia, but not with the inflammation grade of the patients in this group. 
 
Figure 29 TGFB2 expression in the liver tissue and TGFB2 levels in the serum of human PSC and PBC patients from 
different collectives. Expression status of TGFB2 in the liver tissue of individual patients represented as single dots 
(A) in the PSC/PBC cohort from Regensburg, (B) in the GSE79850 cohort with low- and high-risk patients in 
comparison to non-diseased control livers. Low-risk patients responded fully to UDCA treatment. High risk was 
associated with the need for liver transplantation in the course of disease. (C) TGFB2 levels in the sera of matched 
collectives from Mannheim and Frankfurt **p ≤ 0.01, ***p ≤ 0.001; NL= normal liver .  
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GSE79850: Correlation of high-risk vs. low-risk expression  
with clinical characteristics 
 High Risk(n= ) Low Risk (n= ) P 
Scheuer Grade   0,0047 
 I+II 1 6  
III+IV 7 0  
    
Portal Inflammation                 0,1026 
mild 2 5  
moderate 6 1  
    
Interface Hepatitis              0,5804 
None-mild 5 5  
moderate 3 1  
    
Ductopenia   0,0256 
(+) 7 1  
(─) 1 5  
 
Table 7 Correlation between TGFB2 expression and clinicopathological characteristics of 17 PBC patients analyzed 
and described in GSE79850. The expression levels of TGFB2 mRNA were compared between high-risk patients who 
underwent liver transplantation and low-risk patients displaying full response to UDCA treatment. Using Fisher’s 
exact test, significant correlations were observed with Scheuer grade and ductopenia (p <0.05). No correlation with 
portal inflammation nor any diagnosis of interphase hepatitis was observed. 
In one PSC and PBC patient collective (Regensburg), CD45 and PPARG mRNA expression was examined in 
the patients’ tissue. CD45 tended to be upregulated in comparison to normal liver, while no significant 
elevation of PPARG expression was detected (Figure 30A). CD45 expression additionally correlated with 
TGFB2 expression in PSC/PBC patients from this cohort (Figure 30B, p=0.0255). Concurrently, high TGFB2 
expression was detected in the liver tissue of patients with high CD45+ cell infiltration (Figure 30C). Thus, 
the data confirmed a possible mechanistic link between CD45+ cell infiltration and TGFB2 levels, as shown 
in mice (3.1.6.2).  
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Figure 30 Analysis of two inflammation markers in the context of TGFB2 expression in PSC and PBC patients 
(Regensburg cohort). (A) Expression of CD45 and PPARG in PSC and PBC patients was determined. (B) CD45 
expression levels correlated with TGFB2 expression levels of the same patients (pTGFB2/CD45=0.0255; 
rTGFB2/CD45 =0.61). (C) Immunohistochemical staining of TGF-β2 and CD45 in the liver tissue of PSC patients with 
low and high CD45 levels as well as healthy controls (NL). 
3.1.8 Result summary 
In summary, we found that TgfB2 and not, as formerly known, only TgfB1 is a key player in the onset, the 
progress, and the end stages of CLD. In a comparative analysis, we analyzed TgfB2 and TgfB1 expression 
and secretion in murine and human HSCs, hepatocytes, and HCC/hepatoblastoma cell lines. In various 
mouse models reflecting regeneration, acute and chronic liver disease, and human HCC sample cohorts, 
we demonstrated that both isoforms are expressed in different types of liver cells and that expression is 
elevated during the progression of CLD in mouse models in most cases. Although TgfB2 is mostly secreted 
at lower levels than TgfB1, its expression patterns largely follow similar profiles. However, the secretion of 
TgfB2 exceeded that of TgfB1 in some HCC cell lines. Our data indicates a more prominent implication of 
TgfB2 in biliary-derived liver disease models. 
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In this thesis, the anti-fibrotic and immunoregulatory effects of TgfB2 silencing in cholestatic MDR2-KO 
mice have been delineated for the first time. TgfB2 silencing by AONs specifically reduced collagen 
deposition and αSMA expression, but induced anti-fibrotic PparG expression. Accumulation of TGF-β2-
specific AON was detected in macrophage-activated fibroblasts, LSEC, and activated HSCs in mice. This 
was in accordance with TgfB2 expression in these cell types. CD45-positive immune cell infiltration was 
reduced upon TGF-β2-specific AON treatment in the livers of MDR2-KO mice. Furthermore, in PSC and 
PBC patients, TGF-β2 levels were found to be elevated and correlated with CD45-positive immune cell 
infiltration.  
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4 Discussion 
4.1 TGF-β1 and TGF-β2 co-existence in chronic liver diseases 
The main findings of this study have been thouroughly discussed in the accompaying publication (Dropmann 
et al, Oncotarget 2016 [114]). 
4.1.1 Expression in health and disease 
TGF-β1 is known to be a prominent player in hepatocyte destruction, proliferation control [129] and hepatic 
stellate activation [130] inducing a complex process from fibrotic onset of liver disease including 
myofibroplast ,fibroblast activation and ECM deposition to inflammation and late stage CLD. In several 
cancers and diseases, TGF-β and members of its super family have been investigated with regard to their 
involvement and many aspects of their activity have been elucidated [59]. Interestingly, TGF-β isoforms 
share concordant but not redundant functions [32]. We thoroughly investigated the abundance of the TGF-
β1 and TGF-β2 isoform in different liver cell types and damaged livers in different stages of disease. 
Previous studies from Milani et al. [49] identified TGF-β2 occurance solely in bile duct cells along the portal 
tracts and liver lobular zone 1 in rat livers with ligated bile ducts and human fibrotic livers, but no expression 
in normal liver. Like De Bleser [50] and Bissell [48], we could confirm TGF-β2 isoform expression in Kupfer 
cells, LSEC and stellate cells in normal liver and in contrast to dated results from 20 years ago we 
additonally observed TGF-β2 expression in and secretion by hepatocytes. Recent detection methods are 
more sensitive and thus, low or weak signals can be detected. Being hepatocytes the most present cell 
type in liver, we examined TGF-β2 and TGF-β1 in both hepatocyte culture systems, CS (mimicking healthy 
liver tissue) and CM (mimicking diseased hepatocyte surroundings). It has been shown before by others, 
that significant mRNA increment of both isoforms in rat HCs and HSCs over time did not correspond to 
secretion levels of the cytokines suggesting an intracellular use of the newly synthesized TGF-β in the cells 
[131]. Our results in mouse hepatocytes confirmed these findings in both culture systems after 48h . We 
did not focus on cell type specific expression differences of TGF-β2 and TGF-β1 alone, but additionally 
investigated culture method-related behavior as well. Examinations in primary hepatic stellate cells 
revealed up to 10-fold higher TGF-β isoform amounts in the supernatants than in cell lysates after 8 days 
for both cytokines. TGF-β2 protein amounts increased from 2 days to 8 days in culture, while TGF-β1 
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proteins amounts reached a maximum in supernatants and cell lysates at day 2 already, indicating an 
intracellular cytokine specific maximum. Cytokines produced over these amounts are then continuously 
secreted into the supernatant as shown. 
In the study described in this thesis , we could confirm previous data on TGF-β1 and its expression pattern at 
several stages of CLD disease in various models of liver disease including regeneration model as well as 
acute and chronic damage situations [48, 50]. Additionally, we we were able to significantly extent the 
knowledge of TGF-β2 in CLD and HCC. Previous studies have shown that TGF-β2 acts in a profibrogenic 
[39] and tumorigenic manner similar to TGF-β1. Participation of TGF-β2 as a profibrogenic factor could be 
demonstrated by Wang et al. [132] in liver and likewise in other organs when it was administered. 
Coadministration of TGF-β2 and CTGF, but not alone, led to profound tissue fibrosis in three murine mouse 
models. The effect was expressed as a fibrotic response in the abdominal cavity with parenchymal 
involvement. In renal fibrosis, TGF-β2 initiated EMT and induced fibrotic markers such as collagen and 
TGF-β1 in a renal cell line. 
4.1.2 Signaling in health and disease 
Canonical Smad signaling related to TGF-β2 expression was demonstrated when miR-200a treatment lead 
to decreased Smad3 activity and repressed TGF-β2 expression and TGF-β2 treatment to miR-200a 
expression reduction and enhanced Smad3 activity [133, 134]. Neutralisation of TGF-β2 using a monoclonal 
antibody (CAT-152) attenuated renal fibrosis and collagen deposition, further indicating its profibrogenic 
role [67]. First insights reflecting the impact of TGF-β2 in fibrogenic mechanisms were deduced from HCV 
patients. In these patients, TGF-β2 was strongly expressed in stage 3 and 4 of advanced fibrosis and 
correlated well with Smad2 expression [135]. With the information that the human hepatic stellate cell line 
LX-2 is responsive to TGF-β1 and activates the expression of typical fibrotic genes [97], we performed TGF-
β isoform stimulation experiments in LX-2 cells to explore potential receptor expression changes. Although 
TGF-β1 is known to influence receptor expression [115], it did not alter the TGF-β receptor expression in 
LX-2. Interestingly, we could demonstrate that TGF-β2 stimulation remarkably induced TGF-β receptor 
expression after 24h. A major modulator of TGF-β signal transduction is Endoglin, which also facilitate 
cell’s responsiveness to the TGF-β1 and TGF-β3 ligand. Our findings showed that Endoglin is significantly 
upregulated upon TGF-β2 stimulation in HSCs and raise the assumption that TGF-β2 may increase the HSC 
sensitivity to TGF-β1. Facilitated TGF-β1 binding to the receptor may more strongly induce TGF-β1-
mediated stellate cell activation. We have found equal levels of Smad 1,2 and 3 after stimulation with both 
cytokines, but TGF-β2 pretreated LX-2 cells showed elevated Smad1 phosphorylation contrary to TGF-β1. 
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Finally, we could identify TGF-β2 to be differently than TGF-β1 regulated in regard to the Smad pathway. 
Mechanistic details of TGF-β modulation is rare so far. A study on glaucoma showed elevated TGF-β2 
expression in specific Trabecular meshwork (TM) cells. Gremlin-induced TGF-β2 expression was found to 
modulate ECM metabolism in these cells and in tissue by increasing the expression of a variety of ECM 
proteins [36]. Modulation of TGF-β isoforms might be orchestrated by miR-29 members as miR-29 
downregulation by TGF-β2 contributed to the induction of several ECM components as shown by Luna et 
al [41]. Further studies would be required to investigate the detailed mechanisms how TGF-β2 is 
embedded in the signaling and its consequences on gene regulation. 
Whether TGF-β2 may contribute to non-Smad pathways was analyzed by different groups. Sun et al.have 
linked TGF-β2 to the Wnt signaling by miR-200a-mediated suppression of TGF-β2 and β-catenin in the 
context of experimentally induced hepatic fibrosis [136]. The Wnt/ TGF-β2 connection was also supported 
by findings of Biressi et al. [137] in dystrophic muscle cells. Tschaharganeh et al, as well as Dong 
investigated the interaction of TGF-β2 and YAP signaling. Here, YAP, as a mediator of the hippo signaling 
cascade, was upregulated in several cancers including liver cancer.Its modulation in transgenic mice and a 
liver cell line led the discovery of an universal size control mechanism in metazoa and was accompanied by 
strong TGF-β2 induction [138, 139].  
An interdependence of the different TGF-β isoforms in the context of signaling and disease 
regulation was demonstrated by Oh et al. [140]. They demonstrated TGF-β3 upregulation upon 
suppression of TGF-β1 in human cancer cell lines, DU145 (human prostate adenocarcinoma) and 
A375 (human skin melanoma). Thus, both isoforms might be able to compensate for one another. 
They might also share some functions as TGF-β2 silencing induced downregulation of both,TGF-
β1 and TGF-β3. This raises the possibilty of a common transcription factor that regulates TGF-β1 
and TGF-β3 orchestrated by TGF-β2. Additional effects of specific TGF-β isoforms depletion in a 
given tissue type were observed by Horie et al [141]. In their study TGF-β1 and TGF-β2 showed 
diverse effects on target gene regulation on the behaviour of cancer cells and fibroblasts. TGF-β1-
specific depletion in the context of HSC activation in vivo, still led to activation of HSCs. TGF-β2 
and TGF-β3 isoforms did not compensate for the TGF-β1 deficiency [142]. Data from Shimada 
[143] et al. showed TGF-β1 treatment of HSCs affected the expression of TGF-β2 via Rho kinase, 
indicating as well that TGF-β isoforms affect one another.  
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4.1.3 Expression in liver regeneration (acute) and chronically induced liver damage 
By defining TGF-β2 as a possible target in hepatic fibrosis and HCC, our study implies TGF-β2 involvement 
in processes of liver damage, regeneration and proliferation. We further identified an impact of TGF-β2 on 
Smad1 signaling as discussed above, nonetheless, we did not provide any mechanistical data for disease 
development and progression yet. In liver regeneration (acute) modeled by CCl4 intoxification of mice, 
both isoforms showed similar behaviour during the regeneration process and were coincident with 
collagen expression. The dynamics of TGF-β1  expression during this process has been reported for a long 
time, but the comparison might show an analogous importance of TGF-β2. In chronic liver damage 
modeled by CCl4 intoxification through repeated CCl4 injections, synchronous dynamics were observed 
and suggest a congruent function of both isoforms.  
4.1.4 Prominent TGF-β2 expression in biliary-derived liver damage 
When investigating mouse models with biliary-derived liver damage, marked differences of both isoforms 
were demonstrated. TGF-β2 was considerably more induced in bile duct ligated MDR2-KO mouse livers of 
different ages/stages of liver disease progression. Similiary, continious TGF-β2 upregulation with 
advanced bile duct ligation time points was observed, accompanied by a parallel induction of fibrotic genes 
in a study from Abshagen et al.[144]. A link of TGF-β2 to mTOR signaling was drawn by Neef et al. [145] as 
TGF-β2 was downregulated in BDL after Rapamycin treatment. In contrast, TGF-β1 was not regulated in 
this study. Previously, Milani [49] described high TGF-β2 levels in proliferating bile ducts also emphazising 
a possibly role of the TGF-β2 isoform in biliary-derived liver damage. In array analyses from Shackel et al 
[146] including PBC patient samples, TGF-β2 was one prominently regulated gene in parallel with several 
other genes important for inflammation, fibrosis and proliferation. In contrast,a brief study including eight 
twins (E-MTAB-2347) with PBC and non-diseased siblings did not reveal TGF-β2 expression elevation in 
the diseased individuals. 
4.1.5 Expression in cholangiocarcinoma and HCC 
As a conseqence of steady liver damage, liver cancer development may occur. Intrahepatic 
cholangiocarcinoma (ICC) is described to be the second most common cause of liver cancer worldwide. As 
ICC is thought to derive from liver progenitor cells (LPC) and biliary epithial cells (BEC), there is a likelihood 
for deregulated TGF-β2. In line, Sulpice et al [56] analyzed 87 ICC patients and described elevated TGF-β2 
expression in the stroma associated with bad survival, ICC classification, microvascular invasion, and the 
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presence of hilar lymph nodes. Fate tracing experiments in cholangiocarcinoma revealed that biliary cells 
are not the sole cell type of the disease origin as it, may also arise from differentiated hepatocytes [147]. 
Hepatocellular carcinoma (HCC) is thought to arise from hepatocytes .With this knowledge, we further 
investigated TGF-β2 expression in HCC cell lines, in an experimental HCC mouse model and in HCC 
patients in comparision to TGF-β1. 
Our investigations on TGF-β1 expression in different HCC cell lines are in line with past studies [54, 115].Our 
study further showed that nearly all TGF-β1 high expressing cell lines also express high levels of TGF-β2 (r 
= 0.811; p = 0.015). Hep3B and HuH7 cell lines secreted remarkably more TGF-β2 than TGF-β1 implying 
TGF-β2-mediated tumorigenic characteristics. Involvement of TGF-β2 was also reported from 
Tschaharganeh et al [138] where it was downregulated in YAP-deficient HuH7 cells. Other tumorigenic 
features related to TGF-β2 were found in a head and neck squamous cell carcinoma model. In contrast to 
the effects of TGF-β1, TGF-β2 could initiate tumor cell dormancy through TGFβR-I, TGFβR-III and p38α/β 
induction in non-proliferative disseminated tumour cells (DTCs) of a head and neck squamous cell 
carcinoma (HNSCC) model. Further, TGF-β2 treatment of lymph node metastatic cells led to activation of 
pp38, pSmad2 and pSmad1/5 and CDK4 reduction [148]. Taken together, we and others confirm divergent 
and independent effects of both TGF-β isoforms in liver disease.  
Our Oncomine®-based patient analyses confirmed abberant regulations of TGF-β1 and TGF-β2 in HCC and 
cirrhosis. In freely accessible HCC collectives, TGF-β2 upregulation was found in HCC in comparison to 
normal liver, while TGF-β1 was either not regulated or downregulated. Evaluation of the GSE1898 and 
GSE4024 data sets [149, 150], including array data of 121 HCC patients, revealed that patients with high 
TGF-β2 expression levels have poor survival outcome [114]. Since TGF-β2 was found highly expressed in 
tumor stroma by Sulpice et al. , and tumor surrounding tissue is often cirrhotically remodeled, we further 
investigated TGF-β2 levels in cirrhosis and precancerous stages using the datasets domiciled in Oncomine. 
Interestingly, we observed strong TGF-β2 expression in the transition state from normal to cirrhotic tissue. 
Further, TGF-β2 levels were elevated in the serum of cirrhosis patients. We also demonstrated that TGF-
β2 expression in HCC patients was upregulated in comparision to normal liver tissue, while it was found to 
be downregulated when compared to surrounding tissue.  
In our in vivo mouse model of HCC, specifically TGFα/cMyc mice, TGF-β2 expression was as well significantly 
affected in tumors compared to healthy liver. These specific expression changes of both isoforms seems 
to be context dependent and need to be taken into account for further investigations. 
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In summary, for the first time a direct comparision of TGF-β1 and TGF-β2 expression in the progression of 
liver diseases of different etiologies using cell lines, animal models and human patient samples was 
performed. Dependent on the origin of disease, similar (CCl4 intoxification, expression in HCs and HSCs) 
and diverse regulation (MDR2-KO, BDL, human patients samples data arrays) dynamics of both isoforms 
were observed. Thus and in line with previous findings, our study demonstrated that TGF-β1 and TGF-β2 
show equivalent, but also individual and separate functions in liver regeneration and CLD development . 
Thus, future studies should focus on delineating the effects and regulation of TGF-β2 signaling in liver 
diseases, taking into account etiologic and cell type-specific contexts.  
4.2 TGF-β2 inhibition to target biliary derived liver diseases  
Inhibition of TGF-β superfamily and its members has been investigated in various preclinical and clinical trials 
towards the treatment of liver diseases conditions ranging from fibrosis to cancer [59]. Although in some 
studies pan TGF-β approaches were applied that target all three isoforms, TGF-β2-directed tools focus on 
humanized antibodies or AONs mostly. TGF-β2 as a promising druggable target was observed in a study 
in which rabbits received subconjunctival injections of a TGF-β2 neutralizing antibody (CAT-152) post 
glaucoma surgery. CAT-152 significantly yielded in therapeutic benefit by reducing subconjunctival 
scarring and collagen deposition [151, 152]. This observation is line with our findings on amelioration of 
fibrosis upon targeting TGF-β2. 
Based on our results discussed above and the finding that TGF-β2 is upregulated in PSC and PBC patients, 
we concluded that TGF-β2 might represent a promising new candidate to target biliary-derived liver 
disease. Accordingly, TGF-β2 was specifically silenced in early stage biliary disease of MDR2-KO mice by 
using an AON in order to diminish or reverse fibrogenesis. 
AONs exert the ability to selectively target any disease causing gene and thus inhibit its translation to 
effective proteins. High specificity and easy application of AONs make them attractive agents for various 
disease target genes. Extensive  therapeutic attempts have been made in in vivo animal studies and clinical 
trials using AONs in the last twenty years [153, 154]. Insufficient pharmacokinetic efficiency and poor 
cellular uptake were one of the major technical hurdles leading to further developement of next generation 
AONs. To optimize AONs and their biodistribution for (i.g. optimized cellular uptake, half life or binding 
affinity) modifications of their molecular backbone have been untertaken, thus making them to a more 
potent and effective therapeutic tool [155-157]. According to this state of the art requirements, we used 
modified AONs in our study. They were subsequently approved as being well-tolerated by the body system 
as examined by physiological and liver parameter in mice. Systemic application led to a selective 
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downregulation of TGF-β2 in the livers. The different AON uptake of wildtype and disease-activated liver 
cells in MDR2-KO but not in Balb/c mice might be associated with deregulation of chemokine receptors 
and some other genes induced by the control oligo application (placebo effect). 
TGF-β2–targeting AONs were reported before in a study of malignant mesotheliomas in which in vivo and 
in vitro tumor growth reducing effects were reported [158]. These were in line with another cancer study 
that selectively targeted TGF-β2 by a specific AON in glioma tumor cells resulting in antitumor activity ex 
vivo [159], thus showing TGF-β2 as a drugable target. In the past, other TGF-β signaling components and 
fibrosis marker has been successfully targeted not only cancer stages but also in animal models for fibrotic 
diseases. For example, a Timp1 or Timp2-specific AON treatment reduced fibrogenesis in rats and in 
accordance with our data, there was a reduced collagen deposition. However, αSMA, a marker for stellate 
cell activation, was found not to be altered in treated compared to untreated animals [160, 161].The latter, 
is in contrast to our finding, showing significantly reduced αSMA levels in animals treated with TGF-β2 –
targeting AON. Similarly, combinational treatment with TgfB1- and Ctgf-directed AONs reduced CCl4-
induced liver fibrosis as measured by reduced type I collagen expression [162]. 
Inhibition of a well-known endogenous regulatory molecule/ component of TGF-β signaling, Smad7, was 
utilized for the treatment of several diseases before. A result of high SMAD7 levels associated- colitis is 
defective TGF-β1 signaling. Colitis was successfully ameliorated and inflammation reduced in the acute 
phase after oral application of Smad7-directed AONs in murine models [163]. In a clinical study,in which 
Crohn´s disease patients received Mongersen, a Smad7-specific AON, higher remission rates and clinical 
response up to 72% were shown [164];(EudraCT number, 2011-002640-27. 2015) highlighting the 
successful usage of TgfB2-directed AON therapy. 
In our study, we demonstrate that TgfB2 silencing attenuated liver fibrogenesis in MDR2-KO mice, which 
was accompanied by significant a reduction of CD45-positive cell infiltration and upregulation of the anti-
inflammatory and anti-fibrogenic PparG. A relation between TGF-β2 and inflammation has been described 
in several organs and pathologies in previous studies, but not related to liver fibrosis so far. Co-stimulation 
of HUVEC cells with TGF-β2 and IL-1β resulted in EndMT (endothelial to mesenchymal transition) through 
activation of the inflammatory NFΚB signaling as described by Maleszewska et al. [165]. In gastric cancer, 
HSC44PE-stimulated subperitoneal fibroblasts (SPFs) promoted differentiation of monocytes (THP1) into 
M2-like macrophages accompanied by increased expression levels of CSF1, CCL8, CXCL5, and TGFB2.This 
finding characterized specific fibroblasts that regulate the development of an inflammatory niche in 
gastric cell invasion [166]. In liver, our data suggested TGF-β2 as a pro-inflammatory component. In line, if 
silenced, we found a reduction of inflammatory cell infiltrates. Possibly this effect is followed by fibrosis 
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attenuation, although we did not analyze the existence or orientation of a causality so far. In contrast to 
our data, TGF-β2 suppressed LPS-induced macrophage inflammatory responses in the human intestine 
and appeared to have a protective role in the inflammatory injury [167]. In line with our data, Huber-Ruano 
et al [123] showed TgfB2 silencing effects in kidney, breast and lung tumor- derived cell lines. By usage of 
the same AON as used in this thesis, they revealed an inhibition of lung metastatis which might be due, at 
least in part, to CD68 expression induction in tumor associated macrophages (TAMs), thus influencing the 
inflammatory compartment. This is analogue to our data, demonstrating fibrotic and inflammatory 
rearrangements in MDR2-KO mice after TgfB2 depletion and hence possibly confirming regulatory 
function of TGF-β2 in this regard.  
Whether TGF-β2 has a beneficial role on disease development or progression remains unclear and is most 
likely organ,cell type-specific and context-dependent. Mechanistic characterisation of TGF-β2 as a 
regulatory cytokine on fibrogenesis and inflammation in liver is still lacking. The data described in this 
thesis demonstrates a benefical health effect of TgfB2-silencing including downregulation of 
inflammatory cellular infiltrates leading to a reduction of inflammation-and (associated) fibrosis in 
cholestatitic mice. Furthermore, TGF-β2 might also be involved a modulator of the polarisation of liver-
resident F4/80-positive macrophages to a non-inflammatory phenotype. TgfB2-silencing in the MDR2-KO 
biliary fibrosis mouse model, demonstrated a safety profile for AON application, good tolerability as well 
as antifibrotic effects. 
 
In summary, the data presented, provides a strong rationale to examine anti-TgfB2-directed treatment in 
patients with cholestatic liver damage as applies to PSC or PBC. Unfortunately, no curative treatment for 
these rare but destructive diseases are available yet. In line with animal data, these patients exhibit high 
TGF-β2 levels associated with increased CD45 expression.  
Overall, this thesis, points towards TGF-β2 as a promising therapeutic target in CLD especially of biliary 
origin. It further suggests the initiation of clinical trial studies on TGF-β2 inhibition in PSC and PBC patients. 
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